Podcasts about hba1c

Schau dir das Video auf YouTube an und abonniere den Kanal, um keine Folge zu verpassen.ZusammenfassungIn dieser tiefgehenden Episode begrüßt Julia die renommierten Heilpraktiker und Hormonexperten Kyra und Sascha Kauffmann. Gemeinsam beleuchten sie ein oft vernachlässigtes Thema: die Wechseljahre bei Frau und Mann. Sie erklären, welche Hormone – von Östrogen über Testosteron bis hin zu Pregnenolon und DHEA – in dieser Lebensphase eine Schlüsselrolle spielen und wie deren Ungleichgewicht typische Symptome wie Müdigkeit, Gewichtszunahme, Libidoverlust oder Stimmungsschwankungen hervorrufen kann.Kyra teilt ihre persönlichen Erfahrungen mit der Menopause und räumt mit dem Missverständnis auf, dass Testosteron ein rein männliches Hormon sei – es ist für Frauen genauso essenziell für Muskelaufbau, Energie und Libido. Sascha ergänzt die Perspektive des Mannes und beschreibt die Andropause mit ihren eigenen Herausforderungen, die oft unbemerkt bleiben. Die Diskussion deckt auf, warum eine gezielte Hormonbestimmung im Blut sinnvoll ist, um individuelle Ungleichgewichte zu erkennen, und welche weiteren Laborwerte (wie HbA1c) für eine ganzheitliche Betrachtung wichtig sind.Ein Schwerpunkt liegt auf konkreten Lifestyle-Anpassungen zur Verbesserung der Lebensqualität. Kyra und Sascha geben wertvolle Tipps für mehr Bewegung im Alltag (z.B. Wallsit, Burpees) und betonen die Notwendigkeit von Krafttraining für den Muskelerhalt und die Knochendichte im Alter. Sie sprechen auch über die immense Bedeutung von Schlafhygiene – von der Optimierung der Schlafumgebung bis zum gezielten Einsatz von Melatonin als wichtiges Antioxidans. Schließlich motivieren die Experten dazu, die eigene Gesundheit aktiv in die Hand zu nehmen und sich durch kleine Challenges gegenseitig zu unterstützen, um langfristig Hormonbalance und Vitalität zu erreichen. Dieses Gespräch ist ein Muss für jeden, der die Wechseljahre als Chance für mehr Wohlbefinden begreifen möchte!Unterstützt durch MelysiumDiese Folge wird ermöglicht durch Melysium! Schluss mit Chemie auf der Haut? Melysium setzt auf natürliche Hautpflege mit Rindertalg (Beef Tallow), reich an hautfreundlichen Fettsäuren & Vitaminen. Angereichert mit Bienenwachs, Honig & Lavendelöl – ganz ohne Erdöl, Silikone oder Parabene. Pflege, die deine Haut wirklich nährt!Sichere dir 10% Rabatt mit dem Gutscheincode JULIA10 auf deine Bestellung! Hier geht's zu Melysium *Was du in dieser Episode lernst

Ever wondered why a molecule as simple as hydrogen could influence everything from Parkinson's to metabolic syndrome? We explored how molecular hydrogen selectively targets only the most harmful free radicals while leaving beneficial ones alone, making it fundamentally different from every other antioxidant supplement gathering dust in your cabinet.The six-month metabolic syndrome study particularly caught my attention: participants drinking hydrogen water saw improvements in glucose levels, HbA1c, inflammation markers, and even lost weight – with no diet changes or exercise requirements.Tyler breaks down why those expensive alkaline water machines aren't doing what you think (spoiler: it's not about pH), why hydrogen inhalation requires serious safety considerations, and exactly how to dose hydrogen water for maximum benefit.And on top of all this, we tackle why this primordial molecule – literally present since the beginning of the universe – seems almost designed to work with human biology, and why megadoses of vitamins C and E can actually harm exercise performance while hydrogen acts as a fine-tuning modulator.Timestamps:0:00 Hydrogen's effects on major diseases2:45 Six-month metabolic syndrome study results5:15 Hydrogen only targets toxic radicals6:08 Divine properties of hydrogen molecule10:12 Basic chemistry of oxidation and reduction15:30 Dangers of excessive antioxidants23:45 How hydrogen modulates antioxidant systems47:20 Hydrogen production in your gut56:30 Inhaled vs drinking hydrogen water61:15 Explosive dangers of hydrogen inhalation71:30 Therapeutic dosing for hydrogen water85:45 Debunking alkaline and structured water94:30 Tyler's elite athletic performance secretsDisclaimer:Dr. Paul Saladino received his medical degree from the University of Arizona Medical School. His use of "doctor" or "Dr." in relation to himself solely refers to that degree. Dr. Saladino is a licensed physician in California, but he no longer practices in any state and does not see patients so he can focus on educating people full time.This video is for general informational purposes only. It should not be used to self-diagnose and it is not a substitute for a medical exam, cure, treatment, diagnosis, or prescription. It does not create a doctor-patient relationship between Dr. Saladino and you. Always consult your physician before making any health decisions.

Das neue Smart ICT System von Medtronic bringt frischen Wind in die intensivierte konventionelle Insulintherapie – also in den Alltag von Menschen, die mit Pen und CGM leben. Statt Insulinpumpe gibt's hier eine clevere Kombi aus: ✅ CGM-Sensor (Simplera™) – misst automatisch alle 5 Minuten ✅ Smart Insulinpen (InPen™) – merkt sich deine Dosen und erinnert dich ✅ App mit Köpfchen – warnt dich bei verpassten Bolusgaben und gibt Dosierungstipps in Echtzeit Das Ziel: mehr Kontrolle, weniger Stress, weniger Rechnen. -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 130 – Wutbolus – Wenn Dein Insulin zur Waffe wird 118 – Time In Range (TIR) – Zeit im Zielbereich vs HbA1c beim Diabetes 371 – Time in Tight Range – TiTR oder doch lieber Time in Range? Was nu?   Music by by Breakz Studios & Nick Valerson from Pixabay

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sernova has a new partner and a new drug for cell transplants, at home glucose/T1D test research, study looks at best diet for people with type 2, Lifescan files for banktrupcy, T1D Barbie and more! Find out more about Moms' Night Out  Read Hangy Woman's take on Barbie (and send me yours!)  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: In the News July 18   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Sernova is partnering with Eledon Pharmaceuticals to test a new immunosuppressive drug in its ongoing clinical trial for people with type 1 diabetes (T1D). The drug called tegoprubart is designed to protect transplanted islet cells without harsh side effects. The current treatment is known for its potential toxicity, especially towards insulin-producing beta cells, and its adverse side effects, making it less than ideal for islet cell therapy in T1D. Tegoprubart has already shown promise in earlier trials, helping T1D patients achieve insulin independence with better graft survival and fewer side effects. This next phase of Sernova's trial (Cohort C) will combine Eledon's drug with Sernova's Cell Pouch, an implantable device that houses insulin-producing cells. In earlier phases, six participants stopped needing insulin completely, with results lasting years. Sernova also plans to use stem cell-derived islet-like clusters from partner Evotec to create a next-gen therapy. If all goes well, a new clinical program could launch in 2026.   https://www.streetwisereports.com/article/2025/07/15/biotech-partnership-to-revolutionize-diabetes-treatment.html XX Researchers at Yale School of Medicine, funded by Breakthrough T1D, are evaluating GTT@home, a new finger-prick, at-home glucose tolerance test, to monitor early-stage type 1 diabetes (T1D) in individuals with T1D autoantibodies. Developed by Digostics (Dih-jos-tiks), the test offers a simpler, less invasive alternative to clinic-based oral glucose tolerance tests. The study aims to assess its accuracy, usability, and acceptance, potentially paving the way for wider use in early T1D detection and monitoring. The results of the trial will inform future regulatory submissions for GTT@home use in T1D, which already has regulatory approval in the UK, Europe and other regions for other types of diabetes. https://finance.yahoo.com/news/digostics-announces-university-trial-home-164300142.html XX LifeScan announced that it entered into a restructuring support agreement and, to implement it, filed for chapter 11 bankruptcy. As the process moves forward, LifeScan plans to operate in the ordinary course of business. It expects to emerge from chapter 11 by the end of the year. LifeScan develops the OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app that provide simplicity, accuracy and trust in diabetes management. XX New study looks at quality of life and cost of AID systems. This was done in Finland which has the highest prevalence of T1D in the world. The results show automated insulin delivery pumps significantly improved quality of life and reduced diabetes-related complications. The quality-adjusted life expectancy increased by an average of 2.3 years for individuals using an automated insulin delivery pump. Although the overall costs of automated insulin delivery pump treatment were higher than those of conventional insulin pump treatment, its cost-effectiveness ratio was well below the generally accepted willingness-to-pay threshold of 50,000 euros in Finland. This is the first cost-effectiveness study of automated insulin delivery pumps conducted in Finland. https://medicalxpress.com/news/2025-07-automated-insulin-delivery-effective-treatment.html XX Blue Circle Health expands into the 11th state: Louisiana! This is Free, comprehensive virtual clinical care, education, and support program for adults with type 1 diabetes In addition to serving adults with type 1 diabetes in Louisiana, our program is also active in Alabama, Mississippi, Florida, Missouri, Iowa, Ohio, Vermont, New Hampshire, Maine, and Delaware.  The program serves as an extension of participants' existing care teams and ensures continuity of care The organization hopes to inform new care models and policies that remove barriers to healthcare People with T1D over 18 years of age who speak English or Spanish are eligible to enroll. To sign up directly, refer a person living with T1D, or learn how you can partner with Blue Circle Health, visit www.bluecirclehealth.org. XX A new study comparing three popular diets—intermittent fasting, time-restricted eating, and continuous calorie cutting—found that all can help people with type 2 diabetes lose weight and lower blood sugar. But one diet stood out: the 5:2 intermittent fasting plan, where participants eat normally five days a week and restrict calories on two. It led to better results in fasting blood sugar, insulin response, and sticking with the plan. Although researchers identified improved HbA1c levels, and adverse events were similar across the three groups, the IER group showed greater advantages in reducing fasting blood glucose, improving insulin sensitivity, lowering triglycerides, and strengthening adherence to the dietary interventions. https://www.sciencedaily.com/releases/2025/07/250715043351.htm XX MIT students have developed an implantable device.. for use during emergency low blood sugars.   The new implant carries a reservoir of glucagon that can be stored under the skin and deployed during an emergency — with no injections needed.   The researchers showed that this device could also be used to deliver emergency doses of epinephrine, a drug that is used to treat heart attacks and can also prevent severe allergic reactions, including anaphylactic shock. The device contains a powdered form of glucagon and can be remotely triggered—either manually or automatically by a glucose monitor—to release the hormone when blood sugar drops too low. No word on next steps to make this commercially available.   https://news.mit.edu/2025/implantable-device-could-save-diabetes-patients-low-blood-sugar-0709 XX We've covered T1D1 before, this is an insulin calculator app – there's more to it than that.. it was created by 13 year old Drew who lives with type 1, but removed from the apps stores a few years ago, along with other non fda cleared apps. Drew who is now 18, Tells us they just submitted to the FDA and are optimistic about being reinstated. https://www.instagram.com/t1d1app/ XX   XX 1'm Brodie Sargent, a Type 1 diabetic raised in Mudgee, NSW, and currently living in Wollongong.   Starting August 26th, I'll be running a marathon every day for 26 days, and on the 27th day, I'll be finishing with Western Sydney's Half Ironman.   The current world record for the most consecutive marathons run by a Type 1 diabetic male is 25 and I'm aiming to break it.   I'm doing this to inspire others, diabetic or not, to challenge themselves and not let anything hold them back.   Any donation is greatly appreciated and supports a cause I truly believe in. The Type One Foundation focuses on support, connection, awareness, and advocacy for diabetics across Australia. They run online and in-person events for diabetics and their families, and also offer care packages to those newly diagnosed.   I was diagnosed at 15, and it was a tough time for me and my family, we had no history or understanding of diabetes. I was already a shy and awkward kid, and I struggled to speak up about how much it affected me. I started running with my roommate just to kill time but it quickly took over my life. Feeling stuck and unsure where I was heading, I decided to make a change and try to help anyone out there feeling the same way.   You can follow my journey on Instagram: @typerun_   XX Launched during children's congress To further promote inclusivity and tackle the stigma associated with the condition, Mattel partnered with Breakthrough T1D, a global organization dedicated to type 1 diabetes research and advocacy, to launch its first Barbie with type 1 diabetes. This partnership marks a major milestone in Mattel's commitment to greater representation, and highlights Breakthrough T1D's pivotal role in ensuring visibility for the type 1 diabetes community.   The doll is part of the Barbie Fashionistas line and includes key diabetes management tools modeled accurately with the help of Breakthrough T1D. The type 1 diabetes Barbie wears a continuous glucose monitor (CGM) secured with Barbie-pink, heart-shaped tape, and has an insulin pump at her waist. She also comes with a CGM-tracking smartphone, a pastel blue purse, and a blue polka dot outfit – blue being the color that symbolizes global diabetes awareness.   As part of a broader initiative to elevate voices in the type 1 diabetes community, Barbie also partnered with two global role models living with type 1 diabetes: Peloton Instructor Robin Arzón and model Lila Moss.   Robin Arzon Barbie Image Credit: Breakthrough T1D and Mattel Mattel's one-of-a-kind doll based on Arzón features her signature yellow outfit and a crown-shaped CGM on the back of her arm.   In interviews, Moss has highlighted the positive impact that the type 1 diabetes Barbie's visibility has already had, saying she receives daily messages from young people who feel less insecure about wearing their diabetes devices thanks to her public advocacy.   When Linxi Mytkolli, director of patient engagement at Diabetes Action Canada and person with diabetes, heard about the new “Dia Barbie,” she said she teared up.   “I grew up loving dolls, but I never saw one that reflected the reality I now live with – until Dia Barbie. Seeing a doll with a CGM, insulin pump, and even heart-shaped medical tape felt surreal. It's playful, powerful, and personal all at once,” said Mytkolli.   Mytkolli also emphasized that representation and visibility in toys and media can help chip away at shame.   “I've heard from so many people, especially those diagnosed in childhood, who delayed using tech like pumps or CGM because it felt like a punishment. Visibility in toys helps normalize these devices and makes kids feel like they're not alone or ‘othered.' It turns stigma into something softer – something that can be talked about, shared, even celebrated,” Mytkolli said.   And its impact goes beyond people living with diabetes. Laura Pavlakovich, who is the founder and CEO of You're Just My Type and has lived with type 1 diabetes since age five, shared that this representation is equally crucial for those without diabetes, as it demystifies the condition and challenges stereotypes.   “This kind of representation builds a vital bridge of empathy, illustrating that living with diabetes is simply a part of life for millions. It's an essential tool for educating the public and cultivating a more inclusive and supportive society for everyone,” said Pavlakovich.   Pavlakovich shared her personal experience of growing up with diabetes and how this will provide validation for those with the condition who often feel unseen.   “I vividly remember growing up with a 'my twin' doll, custom-made to look just like me, yet she always lacked the crucial part of my daily reality: an insulin pump. To finally see a Barbie, an iconic figure in childhood play, accurately depict someone living with type 1 diabetes, complete with her devices and pump, is truly a monumental moment,” said Pavlakovich.   To celebrate the launch, Barbie donated dolls to the Breakthrough T1D 2025 Children's Congress in Washington, D.C., where 170 young advocates for type 1 diabetes from around the world met with lawmakers to raise awareness. Priced at $10.99, the doll is now available on Mattel Shop and at retailers nationwide.   While this is a huge win for enhancing the representation of children living with diabetes, it doesn't end there. There is still significant work to be done to improve access to diabetes medication and technology.   “It is not lost on me that Barbie has more access to diabetes tech than many, if not most, people with diabetes globally,” said Mytkolli. “Representation and access – we deserve both.”   By bringing a common but misunderstood condition into children's toy boxes, the new type 1 diabetes Barbie is more than a toy. It's a symbol of pride, visibility, and the message that children with diabetes can live full, empowered lives.   As Mytkolli said, “Whether a child is living with diabetes, or loves someone who is, this doll quietly says, ‘You're not broken. You belong.'”

Episode 198: Fatigue.  Future doctors Redden and Ibrahim discuss with Dr. Arreaza the different causes of fatigue, including physical and mental illnesses. Dr. Arreaza describes the steps to evaluate fatigue. Some common misconceptions are explained, such as vitamin D deficiency and “chronic Lyme disease”. Written by Michael Ibrahim, MSIV, and Jordan Redden, MSIV, Ross University School of Medicine. Edits and comments by Hector Arreaza, MDYou are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Dr. Arreaza: Today is a great day to talk about fatigue. It is one of the most common and most complex complaints we see in primary care. It involves physical, mental, and emotional health. So today, we're walking through a case, breaking down causes, red flags, and how to work it up without ordering the entire lab catalog.Michael:Case: This is a 34-year-old female who comes in saying, "I've been feeling drained for the past 3 months." She says she's been sleeping 8 hours a night but still wakes up tired. No recent illnesses, no weight loss, fever, or night sweats. She denies depression or anxiety but does report a lot of work stress and taking care of her two little ones at home. She drinks 2 cups of coffee a day, doesn't drink alcohol, and doesn't use drugs. No medications, just a multivitamin. Regular menstrual cycles—but she's noticed they've been heavier recently.Jordan:Fatigue is a persistent sense of exhaustion that isn't relieved by rest. It's different from sleepiness or muscle weakness.Classification based on timeline:    •   Acute fatigue: less than 1 month    •   Subacute: 1 to 6 months    •   Chronic: more than 6 monthsThis patient's case is subacute—going on 3 months now.Dr. Arreaza:And we can think about fatigue in types:    •   Physical fatigue: like muscle tiredness after activity    •   Mental fatigue: trouble concentrating or thinking clearly (physical + mental when you are a medical student or resident)    •    Pathological fatigue: which isn't proportional to effort and doesn't get better with restAnd of course, there's chronic fatigue syndrome, also called myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), which is a diagnosis of exclusion after 6 months of disabling fatigue with other symptoms.Michael:The differential is massive. So, we can also group it by systems.Jordan:Let's run through the big ones.Endocrine / Metabolic Causes    • Hypothyroidism: A classic cause of fatigue. Often associated with cold intolerance, weight gain, dry skin, and constipation. May be subtle and underdiagnosed, especially in women.    • Diabetes Mellitus: Both hyperglycemia and hypoglycemia can cause fatigue. Look for polyuria, polydipsia, weight loss, or blurry vision in undiagnosed diabetes.    • Adrenal Insufficiency: Think of this when fatigue is paired with hypotension, weight loss, salt craving, or hyperpigmentation. Can be primary (Addison's) or secondary (e.g., due to long-term steroid use).Michael: Hematologic Causes    • Anemia (especially iron deficiency): Very common, especially in menstruating women. Look for fatigue with pallor, shortness of breath on exertion, and sometimes pica (craving non-food items).     • Vitamin B12 or Folate Deficiency: B12 deficiency may present with fatigue plus neurologic symptoms like numbness, tingling, or gait issues. Folate deficiency tends to present with megaloblastic anemia and fatigue.    • Anemia of Chronic Disease: Seen in patients with chronic inflammatory conditions like RA, infections, or CKD. Typically mild, normocytic, and improves when the underlying disease is treated.Michael: Psychiatric Causes    • Depression: A major driver of fatigue, often underreported. May include anhedonia, sleep disturbance, appetite changes, or guilt. Sometimes presents with only somatic complaints.    • Anxiety Disorders: Mental fatigue, poor sleep quality, and hypervigilance can leave patients feeling constantly drained.    • Burnout Syndrome: Especially common in caregivers, healthcare workers, and educators. Emotional exhaustion, depersonalization, and reduced personal accomplishment are key features.Jordan: Infectious Causes    • Epstein-Barr Virus (EBV):Mononucleosis is a well-known cause of fatigue, sometimes lasting weeks. May also have sore throat, lymphadenopathy, and splenomegaly.    • HIV:Consider it in high-risk individuals. Fatigue can be an early sign, along with weight loss, recurrent infections, or night sweats.    • Hepatitis (B or C):Can present with chronic fatigue, especially if liver enzymes are elevated. Screen at-risk individuals.    • Post-viral Syndromes / Long COVID:Fatigue that lingers for weeks or months after viral infection. Often, it includes brain fog, muscle aches, and post-exertional malaise.Important: Chronic Lyme disease is a controversial term without a consistent clinical definition and is often used to describe patients with persistent, nonspecific symptoms not supported by objective evidence of Lyme infection. Leading medical organizations reject the term and instead recognize "post-treatment Lyme disease syndrome" (PTLDS) for persistent symptoms following confirmed, treated Lyme disease, emphasizing that prolonged antibiotic therapy is not effective. Research shows no benefit—and potential harm—from extended antibiotic use, and patients with unexplained chronic symptoms should be thoroughly evaluated for other possible diagnoses.Michael: Cardiopulmonary Causes    •   Congestive Heart Failure (CHF): Fatigue from poor perfusion and low cardiac output. Often comes with dyspnea on exertion, edema, and orthopnea.    •   Chronic Obstructive Pulmonary Disease (COPD): Look for a smoking history, chronic cough, and fatigue from hypoxia or the work of breathing.    •   Obstructive Sleep Apnea (OSA): Daytime fatigue despite adequate hours of sleep. Patients may snore, gasp, or report morning headaches. High suspicion in obese or hypertensive patients.Jordan:Autoimmune / Inflammatory Causes    •   Systemic Lupus Erythematosus (SLE): Fatigue is often an early symptom. May also see rash, arthritis, photosensitivity, or renal involvement.    •   Rheumatoid Arthritis (RA): Fatigue from systemic inflammation. Morning stiffness, joint pain, and elevated inflammatory markers point to RA.    •   Fibromyalgia: A chronic pain syndrome with widespread tenderness, fatigue, nonrestorative sleep, and sometimes cognitive complaints ("fibro fog").Cancer / Malignancy    •   Leukemia, lymphoma, or solid tumors: Fatigue can be the first symptom, often accompanied by weight loss, night sweats, or unexplained fevers. Consider when no other cause is evident.Michael:Medications:Common culprits include:    ◦   Beta-blockers: Can slow heart rate too much.    ◦   Antihistamines: Sedating H1 blockers like diphenhydramine.    ◦   Sedatives or sleep aids: Can cause grogginess and daytime sedation.    •   Substance Withdrawal: Fatigue can be seen in withdrawal from alcohol, opioids, or stimulants. Caffeine withdrawal, though mild, can also contribute.Dr. Arreaza:Whenever we evaluate fatigue, we need to keep an eye out for red flags. These should raise suspicion for something more serious:    •   Unintentional weight loss    •   Night sweats    •   Persistent fever    •   Neurologic symptoms    •   Lymphadenopathy    •   Jaundice    •   Palpitations or chest painThis patient doesn't have these—but that doesn't mean we stop here.Dr. Arreaza:Those are a lot of causes, we can evaluate fatigue following 7 steps:Characterize the fatigue.Look for organic illness.Evaluate medications and substances.Perform psychiatric screening.Ask questions about quantity and quality of sleep.Physical examination.Undertake investigations.So, students, do we send the whole lab panel?Michael:Not necessarily. Labs should be guided by history and physical. But here's a good initial panel:    •   CBC: To check for anemia or infection    • TSH: Screen for hypothyroidism    • CMP: Look at electrolytes, kidney, and liver function    • Ferritin and iron studies    • B12, folate    • ESR/CRP for inflammation (not specific)    • HbA1c if diabetes is on the radarJordan:And if needed, consider:    • HIV, EBV, hepatitis panel    • ANA, RF    • Cortisol or ACTH stimulation testImaging? Now that's rare—unless there are specific signs. Like chest X-ray for possible cancer or TB, or sleep study if you suspect OSA.Dr. Arreaza:Unaddressed fatigue isn't just inconvenient. It can impact on quality of life, affect job performance, lead to mood disorders, delay diagnosis of serious illness, increase risk of accidents—especially driving. So, don't ignore your patients with fatigue!Jordan:And some people—like women, caregivers, or shift workers—are especially at risk.Michael:The cornerstone of treatment is addressing the underlying cause.Jordan:If it's iron-deficiency anemia—treat it. If it's depression—get mental health involved. But there's also: Lifestyle Support: Better sleep hygiene, light physical activity, mindfulness or CBT for stress, balanced nutrition—especially iron and protein, limit caffeine and alcoholDr. Arreaza:Sometimes medications help—but rarely. And for chronic fatigue syndrome, the current best strategies are graded exercise therapy and CBT, along with managing specific symptoms. Beta-alanine has potential to modestly improve muscular endurance and reduce fatigue in older adults, but more high-quality research is needed.SSRI: fluoxetine and sertraline. Iron supplements: Even without anemia, but low ferritin [Anecdote about low ferritin patient]Jordan:This case reminds us to take fatigue seriously. In her case, it may be multifactorial—work stress, caregiving burden, and possibly iron-deficiency anemia. So, how would we wrap up this conversation, Michael?Michael:We don't need to order everything under the sun. A focused history and exam, targeted labs, and being alert to red flags can guide us.Jordan:And don't forget the basics—sleep, stress, and nutrition. These are just as powerful as any prescription.Dr. Arreaza:We hope today's episode on fatigue has given you a clear framework and some practical tips. If you enjoyed this episode, share it and subscribe for more evidence-based medicine!Jordan:Take care—and get some rest~___________________________Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:DynaMed. (2023). Fatigue in adults. EBSCO Information Services. https://www.dynamed.com (Access requires subscription)Jason, L. A., Sunnquist, M., Brown, A., Newton, J. L., Strand, E. B., & Vernon, S. D. (2015). Chronic fatigue syndrome versus systemic exertion intolerance disease. Fatigue: Biomedicine, Health & Behavior, 3(3), 127–141. https://doi.org/10.1080/21641846.2015.1051291Kroenke, K., & Mangelsdorff, A. D. (1989). Common symptoms in ambulatory care: Incidence, evaluation, therapy, and outcome. The American Journal of Medicine, 86(3), 262–266. https://doi.org/10.1016/0002-9343(89)90293-3National Institute for Health and Care Excellence. (2021). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: Diagnosis and management (NICE Guideline No. NG206). https://www.nice.org.uk/guidance/ng206UpToDate. (n.d.). Approach to the adult patient with fatigue. Wolters Kluwer. https://www.uptodate.com (Access requires subscription)Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Ever been told you have type 2 diabetes but left the appointment wondering how that diagnosis was even made? Maybe your A1c looked fine, but your fasting glucose didn't, or vice versa. In this episode, we break down the official diabetes diagnostic criteria in a way that finally makes sense. You'll learn exactly what each test means, how the results are interpreted, and why two people with different test patterns can both be diagnosed correctly.We also share four case studies that highlight just how confusing and conflicting test results can be. You'll find out why one was diagnosed with diabetes despite a normal A1c, and why another skipped straight from “normal” to “type 2,” seemingly overnight with no obvious symptoms.After listening to this episode, you'll have a clearer understanding about what your test results mean and the criteria used to confirm your diabetes diagnosis.CHAPTERS3:35 Hemoglobin A1c test (HbA1c or A1c)4:48 Fasting blood glucose test (FBG)6:10 Oral glucose tolerance test (OGTT)7:02 Random glucose test8:29 EMMA: No symptoms, two high tests on same day9:54 JOHN: Symptoms, one high test12:37 TARYN: Prediabetes A1c, type 2 diabetes OGTT17:41 AMANDA: Normal A1c, high fasting blood sugar23:36 Can diabetes diagnostic tests be inaccurate?For show notes and resources, please visit: https://Type2DiabetesTalk.comTo share your questions and suggestions, leave us a voice message or email at: https://Type2DiabetesTalk.com/messageExplore our proven programs and services, visit: https://Type2DiabetesTalk.com/programsSubscribe to our free weekly newsletter for podcast updates, valuable nutrition tips and more: https://Type2DiabetesTalk.com/subscribe

Schau dir das Video auf YouTube an und abonniere den YouTube Kanal, um keine neue Folge mehr zu verpassen.ZusammenfassungFragst du dich, wie du deine Insulinsensitivität messen oder eine Insulinresistenz testen kannst?

If you care about living longer and better—this episode is for you. Today, we're breaking down the 10 most important health metrics every person should be tracking for longevity, backed by research that ties each one to actual lifespan. No fluff—just the hard-hitting stuff that helps you live longer, move better, and feel more like yourself for years to come. Covering resting heart rate, grip strength, mental health, daily steps, VO₂ max, sleep quality, fiber, blood pressure, waist-to-height ratio, and metabolic labs like HbA1c & ApoB plus: how to track them, what your numbers should be, and realistic ways to improve them—without obsessing over every number on a spreadsheet.This is the kind of episode you'll want to save and come back to. Because your future self will thank you.⁠⁠⁠⁠Sign up for Fitness Stuff PREMIUM here!!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Access to 10+ complete training programsbonus episodes weeklyJust $5 /month⁠⁠⁠⁠Legion Athletics⁠⁠⁠⁠BOGO 50% off for your first order + 2X points on every order after thatuse code “FSPOD” at checkoutTimestamps:(03:00) Resting Heart Rate(06:53) Strength Tests(15:40) Flourishing Scale(18:58) Daily Step Count(26:45) Blood Pressure(35:11) Waist:Height Ratio(39:34) Sleep Quality(42:23) Fiber Intake(53:32) VO2 Max(59:20) HbA1C & Apo B

Our latest podcast episode unpacks the 2025 JAMA Review on Type 2 Diabetes

Program notes:0:40 Stem cells for type 1 diabetes1:40 None had hypoglycemia afterwards2:40 Autologous stem cells?3:20 Oral GLP-1 agonist4:20 Primary endpoint HbA1c reduction5:20 Weight loss modest6:20 Injectable GLP-1 plus an amylin analogue7:20 Both those with diabetes and those without8:20 No increased safety events8:40 Mental health hospitalizations in adolescents9:40 KID database10:40 Females accounting for increase11:40 67% of hospitalizations12:57 End

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, speak with John Buse, MD, PhD, of the University of North Carolina School of Medicine, about the treatment phase of the CATALYST trial. Findings from the phase 4 CATALYST trial suggest that mifepristone (Korlym), a glucocorticoid receptor antagonist, significantly improves glycemic control, reduces body weight, and lowers waist circumference in patients with hypercortisolism and difficult-to-control type 2 diabetes—offering a promising therapeutic option for a population with limited treatment success. The two-part, multicenter study enrolled 1055 adults with type 2 diabetes and HbA1c >7.5% despite optimized therapy. In part 1, participants underwent dexamethasone suppression testing to identify hypercortisolism, defined by post-test cortisol levels >1.8 µg/dL and dexamethasone >140 ng/dL. Results revealed a 24% prevalence of hypercortisolism in this population (95% CI, 21.4–26.7%). Part 2 randomized 136 patients with confirmed hypercortisolism in a 2:1 ratio to receive mifepristone or placebo for 24 weeks. The primary endpoint was change in HbA1c. Mifepristone treatment led to a least squares mean HbA1c reduction of 1.3 percentage points compared to placebo (95% CI, –1.81 to –0.83; P < .001). Secondary endpoints also favored mifepristone: body weight decreased by 5.12 kg (95% CI, –8.20 to –2.03), and waist circumference dropped by 5.1 cm (95% CI, –8.23 to –1.99) relative to placebo. Despite its efficacy, 49% of mifepristone-treated patients discontinued therapy, compared to 18% on placebo. Adverse events included hypokalemia, fatigue, nausea, vomiting, and elevated blood pressure, consistent with the drug's known safety profile. During the episode, which was recorded during the 85th Scientific Sessions of the American Diabetes Association (ADA 2025), Buse provides hosts with a deep dive into the background of the trial, prevalence of hypercortisolism in difficult-to-control type 2 diabetes, and the historic relevance of the CATALYST results. Buse also discusses how the trial offers insight into dosing approaches with mifepristone and advocates for broader cortisol screening in patients with complex type 2 diabetes—suggesting that ADA Standards of Care should reflect these findings. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Relevant disclosures for Buse include Altimmune, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Eli Lilly, embecta, Moderna, Novo Nordisk, Tandem, Vertex, and others.

In this special episode recorded at 85th Scientific Sessions of the American Diabetes Association (ADA 2025), hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, take a deep dive into the REDEFINE 1 and REDEFINE 2 trials with trial investigators W. Timothy Garvey, MD, of University of Alabama at Birmingham, and Melanie Davies, MD, of the University of Leicester. REDEFINE 1 was a 68-week, phase 3a trial enrolling over 3400 adults without diabetes but with obesity or overweight and at least one comorbidity. Participants received once-weekly CagriSema, semaglutide alone, cagrilintide alone, or placebo alongside lifestyle intervention. Key outcome: CagriSema led to a mean weight loss of 20.4%, vs 3.0% with placebo. Over 50% of participants on CagriSema reached a non-obese BMI. Gastrointestinal side effects were common (80%), but mostly mild to moderate. REDEFINE 2 enrolled 1206 adults with type 2 diabetes and overweight or obesity, randomized to CagriSema or placebo for 68 weeks. Key outcome: CagriSema led to 13.7% mean weight loss, vs 3.4% with placebo. 73.5% achieved an HbA1c ≤6.5% vs 15.9% on placebo. Significant improvements were seen across all weight loss and glycemic endpoints. The speakers also highlight the agent's favorable side effect profile, flexibility in real-world dosing, and benefits in body composition and physical function. Garvey emphasizes the shift toward complication-centric obesity care, underscoring the need for clinician-guided treatment beyond online prescription models. The conversation closes with a look ahead to REDEFINE 3—a cardiovascular outcomes trial including patients with and without diabetes—and other ongoing studies in the REDEFINE and REIMAGINE trial programs. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Relevant disclosures for Garvey include Boehringer-Ingelheim, Novo Nordisk, Eli Lilly and Company, Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Fractyl Health, Inc., Inogen, Epitomee, Pfizer Inc., and Neurovalens. Relevant disclosures for Davies include Abbie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GSK, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi, and Zealand Pharma. References: Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. Published online June 22, 2025. doi: 10.1056/NEJMoa2502081 Davies MJ, Bajaj HS, Broholm C. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England Journal of Medicine. Published online June 22, 2025. doi: 10.1056/NEJMoa2502082

Episode 193: Gestational Diabetes IntroJesica Mendoza (OMSIII) describes the pathophysiology of gestational diabetes and the right timing and method of screening for it. Dr. Arreaza adds insight into the need for culturally-appropriate foods, such as vegetables in Mexican cuisine.    Written by Jesica Mendoza, OMSIII, Western University of Health Sciences, College of Osteopathic Medicine of the Pacific. Editing by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.DefinitionGestational diabetes mellitus (GDM) is a condition that occurs to previously non-diabetic pregnant women, caused by glucose intolerance at around the 24th week of gestation. PathophysiologyGDM arises due to an underlying pancreatic beta cell dysfunction in the mother which leads to a decrease in the amount of insulin produced and thus leads to higher blood sugar levels during pregnancy. The placenta of the fetus will produce hPL (human placental lactogen) to ensure a steady supply of sugars to the fetus, creating an anti-insulin effect. However, hPL readily crosses the placental barrier causing the mothers insulin requirement to increase, when the mother's pancreas cannot increase production of insulin to that level needed to counter the effect of hPL they become diabetic, and this leads to gestational diabetes. So, basically the placenta is asking for more glucose for the baby and the mother's pancreas struggles to keep the glucose level within normal limits in the body of the mother. If left untreated, high levels of glucose in the mother can cause glucotoxicity in the mother.“Glucotoxicity” refers to the toxic effect of glucose. Glucose is the main fuel for cell functions, but when it is high in the bloodstream, it causes toxicity to organs. Prevalence of GDM.The CDC reports mean prevenance of GDM is 6.9%. In U.S. mothers the prevenance increased from 6.0% in 2016 to 8.3% in 2021. Many different factors have played a role in increasing gestational diabetes in American mothers, some of those being the ongoing obesity epidemic with excess body weight being a known risk factor for insulin resistance. Another being advanced maternal age (AMA) as more American women have children later in life their body becomes less sensitive to insulin and requires a higher insulin output on top of the insulin that is required for the fetus. The “American diet” is also something that has a big effect in diabetes development. With the increase of high-carb foods that are readily available, the diet of Americans has declined and is affecting the metabolic health of mothers as they carry and deliver their children. Despite ongoing awareness of GDM, 6% to 9% of pregnant women in the United States are diagnosed with gestational diabetes, and the prevalence continues to increase worldwide. It is estimated that in 2017 18.4 million pregnancies were affected by GDM in the world, which then continued to increase to 1 in 6 births to women with GDM in 2019. It was also found that women living in low-income communities were disproportionately affected due to limited healthcare access. Additionally, women with GDM had a 1.4-fold increase in likelihood of undergoing a c-section, with 15% increase in risk of requiring blood transfusion. Screening for GDMGestational diabetes is screened between the 24th to 28th week of gestation in all women without known pregestational diabetes. In women who have high-risk for GDM the screening occurs during the first trimester, these women usually have at least one of the following: BMI > 30, prior history of GDM, known impaired glucose metabolism, and/or a strong family history of diabetes. The screening during the first trimester is to detect “pregestational diabetes” because we have to keep a good glycemic control to improve outcomes of pregnancy. So, if it's positive, you start treatment immediately. If these women are found to have a normal glucose, they repeat the testing again as done normally, at 24-28 weeks of gestation. How do we screen?The screening itself consists of two types of approaches. The two-step approach includes a 50-gram oral glucose tolerance test (OGTT), where blood glucose is measured in an hour and if it is below 140 they are considered to not have GDM, however if the reading is greater than 140 they must then do a 3-hour, 100g oral glucose tolerance test. The 3-hour OGTT includes measuring the blood sugars at Fasting which should be less than 95, at 1 hour at less than 180, at 2 hours at less than 155, and at 3 hours at less than 140. If 2 or more of these values exceed the threshold the patient is diagnosed with gestational diabetes mellitus. The one-step approach includes 75g after an overnight fast. Blood glucose is measured while fasting which should be less than 92, at 1 hour less than 180 and at 2 hours less than 153. If any one of these values is exceeded, the patient is diagnosed with GDM.If the mother is found to be GDM positive during pregnancy she will also need continued screening post-partum to monitor for any development of overt diabetes. The testing is usually 75g 2-hour OGTT at 6-12 weeks postpartum. If this testing is normal, then they are tested using HbA1c every 3 years. If the post-partum testing shows pre-diabetes, annual testing is recommended using HbA1c measurements. Maternal complications Women with GDM are at an increased risk for future cardiovascular disease, T2DM, and chronic kidney disease. GDM is also associated with increased likelihood of developing pre-eclampsia following delivery. Pre-eclampsia is a complication seen in pregnancy characterized by high blood pressure, proteinuria, vision changes, and liver involvement (high LFTs). Pre-eclampsia can then progress to eclampsia or HELLP syndrome, both of which can include end organ damage. Additionally, she can develop polyhydramnios which leads to overstretching of the uterus and can induce pre-term labor, placental abruption, and or uterine atony, all of which additionally put the mother at increased risk for c-section. All of these maternal complications that stem from GDM lead to complications and extended hospitalization. Child's complications Although there is an increased set of risks for the mother, the neonate can also develop a variety of risks due to the increased glucose while in utero. While the fetus is growing, the placenta is the source of nutrition for the fetus. As the levels of glucose in the mother increase so does the amount of glucose filtered through the placenta and into the fetal circulation. Over time the glucose leads to oxidative stress and inflammation with activation of TGF-b which leads to fibroblast activation and fibrosis of the placenta. This fibrosis decreases the nutrient and oxygen exchange for the fetus. As the fetus attempts to grow in this restrictive environment its development is affected. The fetus can develop IUGR (intrauterine growth restriction) leading to a small for gestation age newborn which can then lead to another set of complications. The low oxygen environment can lead to increased EPO production and polycythemia at birth which can then lead to increased clotting that can travel to the newborn brain. Newborns can also be born with fetal acidosis due to the anerobic metabolism and lactic acid buildup in fetal tissues which can cause fetal encephalopathy leading to cerebral palsy and developmental delay. And the most severe of newborn complications to gestational diabetes can lead to fetal demise. Furthermore, the increase of glucose can also lead to macrosomia in the infant which can often lead to a traumatic delivery and delivery complications such as shoulder dystocia and brachial plexus injury. Brachial plexus injury sometimes resolves without sequela, but other times can lead to permanent weakness or paralysis of the affected arm. The baby can be born too small or too big.Additionally, once the fetus is born the cutting of the umbilical cord leads to a rapid deceleration in blood glucose in the fetal circulation and hypoglycemic episodes can occur, that often lead to NICU admission. The insulin that is created by the fetus in utero to accommodate the large quantities of glucose is known to affect lung maturation as well. The insulin produced inhibits surfactant production in the fetus. Upon birth some of the newborns also have to be placed on PEEP for ventilation and some children require treatment with surfactant to prevent alveolar collapse and/or progression to NRDS created by the low surfactant levels. Additionally, neonates who are macrosomic, which is usually seen in GDM mothers, are larger and stronger and when put on PEEP to help increase ventilation the newborn's stronger respiratory effort can lead to higher pulmonary pressures and barotrauma such as neonatal pneumothorax.Long term complications to the child of a mother with GDM also occur. As the child grows, they are also at an increased risk for developing early onset obesity because of the increased adipose storage triggered by the increase in insulin in response to the high glucose in utero. This then can lead to a higher chance of developing type 2 diabetes mellitus in the child. With diabetes, also comes an increase in cardiovascular risk as the child ages and becomes an adult. The effects of GDM go beyond the fetal life but continue through adulthood.What can be done?Gestational Diabetes Mellitus has many severe and lifelong consequences for both the mother and the child and prevention of GDM would help enhance the quality of life of both. Many of the ways to prevent GDM complications include patient education and dietary modifications with a diet rich in whole grains, fruits, vegetables and lean proteins. Benefits of some vegetables in the Mexican cuisine that may be beneficial: Nopales, Chayote, and Jicama. Those are good alternatives for highly processed carbs.Mothers are usually offered nutritional counseling to help them develop a tailored eating plan. This and 30 minutes of moderate exercise daily is recommended to increase insulin sensitivity and lower the post-prandial glucose levels. If within 2 weeks of implementing lifestyle changes alone the glucose measurements remain high, then medications like insulin can be put onboard to manage the GDM. If they require insulin, I think it is time to refer to a higher level of care, if available, high risk OB clinic.Conclusion: Now we conclude episode number ###, “[TITLE].” [summary here]. _____________________References:Eades CE, Burrows KA, Andreeva R, Stansfield DR, Evans JM. Prevalence of gestational diabetes in the United States and Canada: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2024 Mar 15;24(1):204. doi: 10.1186/s12884-024-06378-2. PMID: 38491497; PMCID: PMC10941381. https://pubmed.ncbi.nlm.nih.gov/38491497/QuickStats: Percentage of Mothers with Gestational Diabetes,* by Maternal Age — National Vital Statistics System, United States, 2016 and 2021. Weekly / January 6, 2023 / 72(1);16. https://www.cdc.gov/mmwr/volumes/72/wr/mm7201a4.htm?utmAkinyemi OA, Weldeslase TA, Odusanya E, Akueme NT, Omokhodion OV, Fasokun ME, Makanjuola D, Fakorede M, Ogundipe T. Profiles and Outcomes of Women with Gestational Diabetes Mellitus in the United States. Cureus. 2023 Jul 4;15(7):e41360. doi: 10.7759/cureus.41360. PMID: 37546039; PMCID: PMC10399637. https://pmc.ncbi.nlm.nih.gov/articles/PMC10399637/?utmPerlman, J. M. (2006). Summary proceedings from the neurology group on hypoxic-ischemic encephalopathy. Pediatrics, 117(3), S28–S33.DOI: 10.1542/peds.2005-0620C.Low, J. A. (1997). Intrapartum fetal asphyxia: definition, diagnosis, and classification. American Journal of Obstetrics and Gynecology, 176(5), 957–959.DOI: 10.1016/S0002-9378(97)70609-0.Hallman, M., Gluck, L., & Liggins, G. (1985). Role of insulin in delaying surfactant production in the fetal lung. Journal of Pediatrics, 106(5), 786–790.DOI: 10.1016/S0022-3476(85)80227-0.Sweet, D. G., Carnielli, V., Greisen, G., et al. (2019). European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update. Neonatology, 115(4), 432–450.DOI: 10.1159/000499361.Raju, T. N. K., et al. (1999). Respiratory distress in term infants: when to suspect surfactant deficiency. Pediatrics, 103(5), 903–909.DOI: 10.1542/peds.103.5.903.Burns, C. M., Rutherford, M. A., Boardman, J. P., & Cowan, F. M. (2008). Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics, 122(1), 65–74.DOI: 10.1542/peds.2007-2822.Dabelea, D., et al. (2000). Long-term impact of maternal diabetes on obesity in childhood. Diabetes Care, 23(10), 1534–1540.DOI: 10.2337/diacare.23.10.1534.Dashe, J. S., et al. (2002). "Hydramnios: Etiology and outcome." Obstetrics & Gynecology, 100(5 Pt 1), 957–962.DOI: 10.1016/S0029-7844(02)02279-6.Long-term cost-effectiveness of implementing a lifestyle intervention during pregnancy to prevent gestational diabetes mellitus: a decision-analytic modelling study. Diabetologia.American College of Obstetricians and Gynecologists. (2018). Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstetrics & Gynecology, 131(2), e49–e64. https://doi.org/10.1097/AOG.0000000000002501Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. 

In this Episode we shared why Sea vegetables are the most nutritionally dense plants on the planet and the most abundant source of vitamins and minerals in the plant kingdom.  We highlight Anti-aging, Energy, and daily nutrition.To help us do the heavy lifting we have invited Greg Good, the CEO and Founder of FarmaSea and Sea Veg Whole Food Seaweed supplement.Sea vegetables are packed with protein, iodine, fiber and vitamins A, B, C and E in amounts that are 10 to 20 times higher than land vegetables, while some sea vegetables contain more calcium than milk. Sea lettuce has 25 times the iron found in beef. Which is great for people who can't have beef or prefer not to.An 8-week study of 60 Japanese people revealed that fucoxanthin, a substance in brown seaweed, may help improve blood sugar control.Another substance in seaweed called alginate prevented blood sugar spikes in animals after they were fed a high-sugar meal. It's thought that alginate may reduce the absorption of sugar into the bloodstream.A 2023 meta-analysis Trusted Source found that brown seaweed consumption significantly improved blood glucose, glycated hemoglobin (HbA1c), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).Anyone who wants help to feel more natural energy, take a preventative approach to their health, manage the effects of aging, and look to bridge the nutritional gaps currently they're not getting in their daily diet. Check out Superfoodofthesea.com or at 855-627-9929 to ensure that you get the high quality of pure Sea Veg products.For Forever Young Listeners for a limited time, you can get 3 bottles of the (90) original Sea veg for $60. Just use the code FY3460 (This is for first time orders only).

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, are joined by Roy Beck, MD, PhD, executive director of the Jaeb Center for Health Research, to discuss the INHALE-3 trial, an adult study evaluating technosphere inhaled insulin (Afrezza) in comparison to standard diabetes therapies, including automated insulin delivery (AID) systems. Beck outlined his center's transition from ophthalmology-focused research to becoming a key player in diabetes trials over the last 25 years, particularly in technology-driven therapies. The conversation explores inhaled insulin's pharmacokinetic profile—its rapid onset and short duration, which more closely mimics physiologic insulin responses than injected rapid-acting analogs. The INHALE-3 trial randomized adults with type 1 diabetes (T1D), including nearly 50% who were on AID systems, to either continue their current regimen or switch to once-daily insulin degludec plus Afrezza for meals and corrections. Surprisingly, Beck highlighted participants willing to suspend AID use to try the inhaled approach, allowing for a head-to-head comparison. The study met its primary non-inferiority endpoint for HbA1c, with outcomes from Afrezza plus basal insulin comparable to those achieved with AID and multiple daily injections. However, Beck emphasized the heterogeneity in response. Approximately 30% of participants switching to Afrezza achieved notably better glycemic control (including greater reductions in HbA1c and less time >250 mg/dL), while a similar proportion performed worse, largely depending on their engagement and dosing frequency. CGM use was required in the study, enabling patients to re-dose Afrezza postprandially as needed, a key factor in those who succeeded. Beck also indicated that overnight glycemic control remained a challenge. While Afrezza performed well during daytime periods, AID systems outperformed it overnight—an expected finding given AID's strength in basal modulation. Weight gain was also lower in the Afrezza group, offering an additional potential advantage. Hosts discussed real-world use cases combining AID with Afrezza, with Beck sharing his son's personal success using Afrezza alongside Tandem Diabetes' Control-IQ in sleep mode, a workaround to prevent algorithmic overlap. He noted future integration could be more seamless with upcoming Bluetooth-enabled Afrezza inhalers or AID systems capable of receiving inhalation data. Safety data showed bronchospasm was rare in the trial, with no confirmed cases attributable to Afrezza. Cough was the most common side effect, generally mild and transient, while active asthma and smoking remained contraindications. Isaacs and Bellini highlighted Afrezza's potential as an underutilized but powerful option in the diabetes toolkit, particularly for patients seeking alternatives to injections or pumps, or looking for greater control over postprandial excursions. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Chapters 00:00:01 Introduction and Background of Dr. Roy Beck 00:02:16 Overview of Inhaled Insulin 00:06:31 INHALE-1 Pediatric Study 00:07:21 INHALE-3 Adult Study 00:11:18 Study Results and Participant Outcomes 00:19:57 Challenges and Future Directions 00:26:44 Side Effects and Safety Concerns 00:31:09 Conclusion and Final Thoughts

Joe Kiani, founder of Masimo and current leader of Willow Laboratories, joins The Digital Executive podcast to discuss his mission to turn once-impossible health innovations into accessible tools for everyday wellness. At Masimo, Kiani revolutionized non-invasive patient monitoring; now at Willow Laboratories, he's applying that same visionary approach to personalized health management with the Nutu app.Nutu, developed by Willow Laboratories, blends cutting-edge science with behavioral insights to help users make smarter decisions around food, activity, and sleep—backed by a personalized "Nutu Score." With real-world outcomes like reduced HbA1c levels and expanded global reach on the horizon, Joe shares how technology can reshape our health span.

In this episode, we sit down with Dr. Matthew Dawson, the founder and CEO of Wild Health, and leader in genomics-based precision medicine. Dr. Matt breaks down what precision medicine truly means--how it goes beyond traditional healthcare to create highly personalized plans based on your unique genetic blueprint and blood work. We explore some of the most important genes to assess for optimizing health, performance, and longevity, including the ApoE gene. He shares powerful insights into the future of medicine and why understanding your genetics is crucial for extending healthspan. Plus, we open up about our own personal Wild Health test results and how they've shaped our individual wellness journey. This conversation is packed with actionable insights you won't want to miss!Dr. Matthew Dawson is the founder and CEO of Wild Health, a genomics-based precision medicine company, and the CEO of TruDiagnostic, an epigenetics testing lab. He has authored two textbooks, published over two dozen studies, lectured in over 20 countries, and won national awards for education and innovation. His passion is unlocking the secrets of the genome and epigenome and using them to optimize health and maximize healthspan. He lives in the woods with his wife, four children, and two dogs.SHOW NOTES: 0:31 Welcome to the show!3:57 Dr. Matt Dawson's Bio4:40 Welcome Dr. Matt to the show!5:14 What is “Precision Medicine”?7:14 Your genes are not your destiny11:09 Renee's experience with Bulletproof coffee11:38 MTHFR & Homocysteine12:43 Combining lab work with genetics17:24 Alzheimer's genetics20:32 What to do for APOE-3/422:56 Biomarkers for optimal health 24:28 Can you change your sleep chronotype?28:26 Genes for telomere length31:37 *ALIGN MAT*33:16 *PIQUE TEA*35:27 Boosting BDNF37:30 Something new about HbA1C!39:47 FOXO3 Gene for Longevity43:40 Blue Zones & social connection45:12 Testing Biological Age49:08 Caloric Restriction for Longevity51:42 The perfect diet for your genes53:25 Comparing macro tolerances57:37 Wild Health reports 59:12 Coming soon for Precision Medicine!1:04:16 His final piece of advice1:04:56 Thanks for tuning in!RESOURCES:Website: wildhealth.com - discount code: BIOHACKERBABESInstagram: wildhealthmdLinkedIn: Wild HealthMy Align Mat - discount code: BIOHACKERBABES to save $250Pique Tea - Save $ with this link!Puori - Save 20% with discount code: BIOHACKERBABESEffecty - Save $50 with discount code: BIOHACKERBABESOur Sponsors:* Check out Effecty and use my code BIOHACKERBABES for a great deal: https://www.effecty.com* Check out Puori: https://Puori.com/BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

PODCAST - LAS NOTICIAS CON CALLE DE 25 DE ABRIL - Ninguna empresa quiere venir a PR a administrar sistema eléctrico - El Nuevo Día - APPLE va a cambiar a producir de India en vez de China para iPhones hacia Estados Unidos - Financial Times- Vacas que aguantan calor nacen en PR - El Vocero - Gobernadora dijo que no va a retirar nombramiento de Estado - Cuarto Poder - Todos los actores en caso del BDE y su corrupción finalmente llegan a proceso judicial - El Nuevo Día - Presidenta CEE se auto dio un bono sin autorización de la Junta - El Nuevo Día - Podrían aumentar la luz para poder pagar gastos operacionales - El Vocero - Piden a federales que le den permisos ya a LUMA para vegetación - El Vocero - Placas solares llegan al aeropuerto - El Vocero - Caos brutal en hospital Auxilio Mutuo - El Vocero - Dicen leyes de cabotaje son buenas para PR - El Vocero - Maltrato animal por las nubes y sueltan 20 perros en Isabela - Primera Hora- China le dice a Trump que si quiere negociar empiece con quitar tarifas - Financial Times- Trump quiere presionar a Ucrania a aceptar acuerdo de paz que básicamente le da todo a Putin - Tapón por camión volcado de Caguas a Cayey - Policía- China considera exenciones a algunos productos para evitar tarifas - CNBC- Trump vende gorras de Trump 2028 - Cuarto Poder - 500 personas pidieron protección para huir de parejas maltratases - Metro - Trump a Europa para el sepelio del Papa Participa de este estudio de clínico: TRANSEND-T2D-3¿Tienes diabetes tipo 2 y enfermedad renal crónica?Este estudio de investigación clínica podría interesarte

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Eli Lilly will start a lcinical trial for tirzepatide for people with type 1 diabetes, more details on Dexcom's 15 day G7 sensor, Ozepmic pill form tested, type 5 diabetes identified and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week.. Eli Lilly takes the first steps toward getting tirzepatide approved for people with type 1 diabetes. Tirzepatide is sold under the brand names Mounjaro for type 2 and Zepbound for obesity. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or are overweight. Participation in the study will last about 49 weeks. Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight This is a big deal because, even though many people with type 1 are able to get a prescription for tirzepatide, it's not approved for T1D and so insurers won't usually cover it.   https://clinicaltrials.gov/study/NCT06914895 XX The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there's little information on the drugs' safety and effectiveness for the condition. The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can't make enough of their own. Drugmakers feared that using the GLP-1 medications with insulin might raise the chance of dangerously low blood sugar events, or hypoglycemia, and were unwilling to take the risk of studying them in people with type 1.   For the study, which was published last month in the journal Diabetes, Obesity, and Metabolism, researchers at Johns Hopkins University reviewed the medical records of more than 200,000 people with type 1 diabetes from 2008 to 2023. They grouped the data in three-year periods, starting with October 2008 to September 2011 and ending with October 2020 to September 2023. GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase. But these are anecdotal reports and may not reflect instances in which people have side effects or complications like low blood sugar, which can be life-threatening. But Shin says what's really needed is information from randomized, double-blinded studies, in which participants are followed forward in time and given either a drug or a placebo. https://www.cnn.com/2025/04/09/health/glp-1-type-1-diabetes-study/index.html   XX Later this month the FDA will conduct a final meeting regarding a new, investigational compound (sotagliflozin) soda-GLIFF-a-zin that has been shown to Improve QoL and Reduce Long-term Complications for people with type 1 diabetes (T1D). The patient advocacy group Taking Control of Your Diabetes (TCOYD.org) is working to inform the T1D community about sotagliflozin - and to encourage people to sign a Change.org petition directed towards FDA.  Last fall, the FDA declined to approve sotagliflozin due to concerns about a potential increased risk of diabetic ketoacidosis (DKA), despite this being a condition that people with T1D on insulin face and manage daily. While TCOYD respects FDA's caution, the group stands by T1D patients and their physicians who, as a team, balance risks and benefits every day. https://tcoyd.org/petition/ XX Dexcom receives FDA approval for it's G7 with 15 day wear. We have an interview with Chief Operating Officer Jake Leach coming up on Tuesday – we talk about the planned roll out of this sensor, what else has changed, and the fine print in the press release – it says    “A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days.   https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx?utm_source=www.diabetech.info&utm_medium=referral&utm_campaign=dexcom-g7-15-day-sensor-gets-fda-cleared-but-will-it-actually-last-that-long   XX Glucotrack is joining something called  FORGETDIABETES bionic pancreas initiative, - this is an European Union project that aims to develop a long-term automated insulin delivery system for type 1 diabetes patients. Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.   The architecture of BIP encompasses a ground-breaking, lifelong lasting implanted ip glucose nanosensor; a radically novel ip hormone delivery pump, with unique non-invasive hormone refill with a magnetic docking pill and non-invasive wireless battery recharge; an intelligent closed-loop hormone dosing algorithm, optimized for ip sensing and delivery, individualized, adaptive and equipped with advanced self-diagnostic algorithms.     Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of pain and awkward daily measurement and treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. key feature of BIP is to be fully-implantable and life-long lasting thanks to novel biocompatible and immune-optimized coatings guaranteeing long-term safety and stability https://www.stocktitan.net/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-cjjldjb0dq7h.html XX A newly recognised form of diabetes, called Type 5, was announced this week at the World Congress of Diabetes 2025. A global task force will investigate this less-understood condition, which differs from Type 1 and Type 2 diabetes. Type 5 diabetes affects people who are underweight, lack a family history of diabetes and do not show the typical symptoms of Type 1 or Type 2 diabetes. The condition was first observed in the 1960s and referred to as J-type diabetes, after being detected in Jamaica. It was classified by the World Health Organisation in 1985, but removed in 1998 due to lack of physiological evidence. At the time, experts believed it to be a misdiagnosed case of Type 1 or 2 diabetes. New research has since confirmed that Type 5 is different. https://economictimes.indiatimes.com/news/new-updates/a-new-type-of-diabetes-has-been-found-by-scientists-and-it-doesnt-show-the-typical-symptoms-of-type-1-or-type-2/articleshow/120276658.cms?from=mdr   XX Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. A new clinical trial, co-led by endocrinologist and diabetes specialist John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine, has demonstrated that the oral form of semaglutide significantly lowers the risk of cardiovascular events in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease. Results from the rather large, international trial were published in the New England Journal of Medicine and presented at the American College of Cardiology's Annual Scientific Session & Expo in Chicago, Illinois.     The effect of oral semaglutide on cardiovascular outcomes was consistent with other clinical trials involving injectable semaglutide, but more trials are needed to determine if one method may be more effective than the other at reducing major cardiovascular events. https://scitechdaily.com/new-pill-form-of-semaglutide-shows-major-benefits-for-people-with-diabetes/ XX April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States. Novo Nordisk, the Danish-headquartered manufacturer, informed the FDA on April 3 that counterfeit 1-milligram injections of semaglutide were being distributed outside its authorized supply chain. The FDA and Novo Nordisk are testing the fake products to identify whether they're safe. Patients are asked to obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for any signs of counterfeiting. People in possession of the fake product are urged to call Novo Nordisk customer care at 800-727-6500 Monday through Friday from 8:30 a.m. to 6 p.m. EDT and report it to the FDA's criminal activity division's website. Side effects can be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program (800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, at 800-727-6500. https://www.upi.com/Health_News/2025/04/14/FDA-fake-Ozempic-drugs-Novo-Nordisk/6841744666854/ XX Can a digital lifestyle modification program reduce diabetes risk? A new study shows that the lifestyle intervention significantly reduced 10-year diabetes risk among prediabetics by nearly 46% and increased the diabetes remission rate, highlighting the importance of lifestyle changes. However, the study was not a randomized trial, and participation in the lifestyle intervention was voluntary, which may introduce selection bias. The study evaluated 133,764 adults, categorizing them as diabetic (7.5%), prediabetic (36.2%), and healthy (56.3%), based on fasting glucose and HbA1c levels. https://www.news-medical.net/news/20250414/Digital-lifestyle-program-cuts-diabetes-risk-by-4625-in-prediabetics-study-of-130k2b-adults-reveals.aspx XX Chrissy Teigan is speaking out about her son's type 1 diagnosis – teaming up with Sanofi to encourage people to screen early for Type 1 diabetes.   Teigen got a crash course in the risks of undiagnosed Type 1 diabetes when her 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease last year. The family knew nothing about Type 1 diabetes when Miles was diagnosed during an unexpected medical emergency, Teigen said in a Tuesday announcement. “We were confused and scared when Miles was first diagnosed,” she said in a statement. “There is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!”   Teigen shared her family's story in a two-minute video on ScreenForType1.com, a Sanofi website that discusses how to get screened for the condition. Miles' diagnosis made Teigen feel like she “went from a mom to a doctor overnight,” she said. That experience is why Teigen said she is “begging you: Do this one thing, and screen yourself and your family for Type 1 diabetes.” https://www.fiercepharma.com/marketing/sanofi-signs-chrissy-teigen-diabetes-screening-campaign XX Dr. Richard Bernstein – best known for his advocacy around low carb diets for people with diabetes – died this week at the age of 90. Born in 1934 in Brooklyn, New York, he was diagnosed with type 1 at age 12. In the 1970s he adapted a blood glucose monitor for home use and helped pioneer home glucose monitoring. He published multiple books on Diabetes including the #1 selling Diabetes book on Amazon.Com “Dr. Bernstein's Diabetes Solution: A Complete Guide to Achieving Normal Blood Sugars” and “Diabetes Type II: Living a Long, Healthy Life Through Blood Sugar Normalization”.  He practiced and saw patients right up until his death.

Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears smart belt device reduce fall injury.

In this episode, Tara breaks down why blood work is one of the most powerful tools for navigating your health — especially in perimenopause and midlife. She explains how conventional medicine often relies on lab ranges based on unhealthy population averages, which can leave many women feeling dismissed even when they don't feel well. Instead, Tara advocates for interpreting labs through a functional, optimal range lens, offering a clearer, more personalized picture of what's really happening in your body. She dives into the most important blood markers to monitor annually to protect against risks like dementia, heart disease, osteoporosis, and type 2 diabetes — including fasting insulin, glucose, HBA1C, glycomark, cholesterol ratios, and liver health indicators. Tara also highlights the nuances of thyroid and iron metabolism in midlife, why oversimplified interpretations can lead to missed diagnoses, and how comprehensive reviews can uncover root causes behind symptoms like fatigue, weight gain, and brain fog. This episode is packed with empowering, actionable information to help you advocate for better care, understand your body's signals, and make informed, proactive choices for your health.   What You'll Learn in This Episode: Comprehensive Blood Work Reviews - Discover the difference between a standard blood test review and a deep dive into the nuances of your results. Interpreting Lab Reference Ranges - Learn why the traditional lab ranges might not always reflect the healthiest standards. Key Metabolic Markers - Understand which markers are essential to monitor for optimal metabolic health and why they're critical as we age. Iron and Vitamin D Insights - Find out why relying solely on ferritin for iron levels and high doses of vitamin D might not be the best approach. Thyroid Health Nuances - Explore the complexities behind thyroid markers and why a comprehensive test is more telling.   Your health didn't decline overnight—it took decades of stress, diet choices, and life events to get to this point. True healing requires commitment, patience, and consistency. The women who succeed are the ones who stay the course, even when progress feels slow. If you're ready to commit to deep, lasting change, BOOK A CONSULT WITH TARA HERE.   You may also enjoy these episodes: Episode 123: Caution should be taken when supplementing vitamin D, iron & selenium. Do not DIY these supplements! Episode 22: All about cholesterol, (& how it doesn't cause heart disease).   Mentioned in this episode: EQUIP PRIME PROTEIN – Click HERE to grab yours and use my code: TARA20 to get 20% off HRT Made Simple™ - Learn how to confidently speak to your doctor about the benefits of hormone replacement therapy so you can set yourself up for symptom-free, unmedicated years to come without feeling confused, dismissed, or leaving the medical office minus your HRT script. Hair Loss Solutions Made Simple™ – This course will teach you the best natural, highly effective, and safe solutions for your hair loss so you can stop it, reverse it, and regrow healthy hair without turning to medications. The Hormone Balance Solution™ – My signature 6-month comprehensive hormonal health program for women in midlife who want to get solid answers to their hormonal health issues once and for all so they can kick the weight gain, moodiness, gut problems, skin issues, period problems, fatigue, overwhelm, insomnia, hair/eyebrow loss, and other symptoms in order to get back to the woman they once were. [FREE] The Ultimate Midlife Perimenopause Handbook - Grab my free guide and RECLAIM your confidence, your mood, your waistline and energy without turning to medications or restrictive diets (or spending a fortune on testing you don't need!).  

Diabetes Wake-Up Call: The Silent EpidemicIn this episode of Fat Science, Dr. Emily Cooper, Andrea Taylor and Mark Wright take on a troubling statistic—half of American adults are either diabetic or prediabetic, and for those with prediabetes, 8 in 10 don't know it. Think about your own family. The odds are one in two of your loved ones are at risk.The good news is diagnosing diabetes is easy, and in many cases it's reversible. Dr. Cooper breaks down the tests you should get, the numbers to look for and the top treatments. Taking control of your diabetes risk just could save your life. Key Takeaways:Diabetes affects nearly half of the U.S. population, with approximately 80% of prediabetes cases undiagnosed.Type 1 diabetes requires lifelong insulin therapy, while type 2 is often linked to genetic predisposition and lifestyle, with potential for reversal.Regular screening for glucose (blood sugar) and HbA1c levels (your long-term blood sugar average) is crucial for early detection of prediabetes and diabetes, applicable to both adults and children from age 10.Managing diabetes involves a comprehensive approach, including diet, exercise, lifestyle modifications, and medications like metformin and GLP1's.Medications are not a failure but a crucial tool in preventing severe complications and maintaining a high quality of life.Resources:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, send an email to dr.c@fatsciencepodcast.com. If you have a show idea, feedback, or just want to connect, you can also reach us us at info@diabesityinstitute.org.

Guest: Greg Good, the CEO and Founder of FarmaSea and Sea Veg Whole Food Seaweed supplement.Sea vegetables are packed with protein, iodine, fiber and vitamins A, B, C and E in amounts that are 10 to 20 times higher than land vegetables, while some sea vegetables contain more calcium than milk. Sea lettuce has 25 times the iron found in beef. Which is great for people who can't have beef or prefer not to.An 8-week study of 60 Japanese people revealed that fucoxanthin, a substance in brown seaweed, may help improve blood sugar control.Another substance in seaweed called alginate prevented blood sugar spikes in animals after they were fed a high-sugar meal. It's thought that alginate may reduce the absorption of sugar into the bloodstream.A 2023 meta-analysis Trusted Source found that brown seaweed consumption significantly improved blood glucose, glycated hemoglobin (HbA1c), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).Anyone who wants help to feel more natural energy, take a preventative approach to their health, manage the effects of aging, and look to bridge the nutritional gaps currently they're not getting in their daily diet. Check out Superfoodofthesea.com or at 855-627-9929 to ensure that you get the high quality of pure Sea Veg products.Forever Young Listeners for a limited time, you can get 3 bottles of the (90) original Sea veg for $60. Just use the code FY3460 (This is for first time orders only).

The SOUL trial

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog If you are receiving testosterone or estradiol hormone pellet therapy, BioBalance Health wants to know if you have any of the following medical conditions that may require you to take antibiotics before any medical or dental procedure that breaks the skin, including pellet insertions and dental cleanings. BioBalance Health is dedicated to providing safe and effective hormone replacement with pellets for both men and women, and we want to ensure your health and safety throughout the process. We use sterile procedure guidelines, but certain conditions still require antibiotics to prevent local infections.   Conditions That May Require Pre-Procedure Antibiotics: If You Have Had a Joint Replacement.Some orthopedic surgeons recommend that patients take antibiotics before dental procedures to prevent infection in the joint that was replaced, while others may not. It is important that you follow the advice of YOUR orthopedic surgeon regarding antibiotics before any procedure. If your orthopedic surgeon has advised you to take antibiotics, please let us know. We can provide you with an antibiotic injection or a prescription to take the day of your pellet insertion that will prevent infection. If You Have Uncontrolled Type 1 or Type 2 Diabetes. If your blood sugar is not well-controlled, you may need antibiotics before your pellet insertion to prevent infection of the pellet insertion area. If you are treated and keep your sugars in good control you may not need antibiotics, however if your diabetes is in poor control, you are more likely to get an infection. It is important that you take antibiotics before your pellet insertion. The following blood sugar levels are considered indicators of poor diabetes control: HbA1c > 9.0 Fasting blood sugar > 150 mg/dL If your blood sugar exceeds these levels, or if your primary care doctor has recommended that you take antibiotics before dental cleanings or procedures, you should also take antibiotics before your pellet insertion to reduce the risk of infection.  If You Have an Autoimmune Disease and are on Immunosuppressive Treatment. If you are receiving treatment for an autoimmune condition that suppresses your immune system, you may be at higher risk for infection at the insertion site. In this case, you will need to take antibiotics before each pellet insertion. If your Rheumatologist does not believe antibiotics are necessary for you, you may proceed without them.  If You Are Receiving Cancer Treatment. Certain cancer treatments, especially those that suppress white blood cell production, can compromise your immune system. If you are undergoing such treatment, you should take antibiotics before or with your pellet insertion to prevent infection.   In Summary: If a doctor has advised you to take antibiotics for procedures, such as dental cleanings, you should also take antibiotics before your pellet insertion. Please inform us of any conditions or treatments that may require this precaution, and we will ensure you are properly prepared for your procedure.

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog Last time we reviewed why interpreting your lab may lead you to the wrong diagnosis and treatment.  Today we continue our review of each lab panel and why the reference ranges on your lab results may not be the “Healthy Normal Range” that you should compare your results to. Lab reference ranges are established with a one-size-fits-all mentality, ignoring the numerous variables that influence blood results. Have you ever tried on a “one-size-fits-all “ANYTHING? Those clothes may fit 20% of the population but for the rest of us, the garment doesn't fit our width, weight or height! All one-size-fits-all lab reference ranges are much the same.  For example, the standardized “reference ranges” in the US serve as a one-size-fits-all “ideal range” applied to everyone, despite genetic differences, varying latitudes, and the diverse diets that characterize the American multiethnic population. This presents the first problem with using a single range for all people: variations among individuals based on differing genetic needs.  The second issue is that the ranges on the lab report indicate the minimum levels necessary for survival, not necessarily the healthiest blood levels for most individuals. Another example of one size doesn't fit all is the reference range for women's hormones. A range is displayed for cycling women, but there is no healthy range for menopausal women.  Does the range displayed refer to menopausal women with HRT, or menopausal women without HRT to treat their menopausal symptoms? Is the range based on what is healthy, or what is average? We aren't sure. Labs don't ask patients questions that could help interpret lab values. Therefore, they cannot provide a truly diagnostic reference range for any illness. They only consider gender and age, as reference ranges are solely adjusted for these two factors.  A doctor must interpret individual lab results alongside a patient's medical and surgical history, including established diseases, medications, supplements, hormonal treatments, and past lab values. For instance, laboratory companies should offer reference ranges based on whether a patient is menopausal, a woman is undergoing ERT, a man is receiving testosterone, a patient is on thyroid medication, a person is being treated for diabetes, or the diabetic tests are performed to diagnose diabetes.   Some Reference Ranges are Based on comparing results to Misleading formulas The best example of this issue is the Lipid Panel. Doctors use this panel to determine a person's risk for heart attacks caused by atherosclerosis. Most doctors don't know the formula for determining Total Cholesterol. This test doesn't predict heart disease in most patients, as the formula used to arrive at that number is not indicative of the disease. However, doctors have been advised that when   total cholesterol levels are high, a patient should start taking a statin, a drug that reduces blood cholesterol and sometimes lowers the rate of heart attacks in certain individuals, though it is rarely predictive in 50% of the population. The problem with the lipid panel is twofold: the LDL level indicates future atherosclerosis in only about 50% of the population and is not a specific test for future heart disease risk. Total cholesterol is even less predictive of heart disease because it stems from a flawed formula. Doctors interpret a high Total Cholesterol level as an indication that a patient may be at increased risk for heart disease in the future. When I test patients with elevated Total Cholesterol or high levels of LDL using a Cardiac Calcium Scan to measure plaque, only half of them actually produce plaque, and consequently, are not at risk for atherosclerotic heart disease. I believe that the Total Cholesterol number is derived from an inaccurate formula for determining a person's risk of future heart disease. The Total Cholesterol number is calculated using a flawed equation. The equation is as follows:         LDL + 1/5 Triglycerides+ HDL = Total Cholesterol Total Cholesterol = LDL (bad cholesterol) + 1/5 Triglycerides (high risk factor) + HDL (good cholesterol) Let's examine this formula simply like this:   Bad + Bad + Good does not equal Bad. Due to this incorrect formula, thousands, if not millions, of patients have been prescribed statin drugs for a lifetime without justification!  Statins carry risks. The list of side effects is extensive and includes muscle deterioration and statin-associated dementia. Unfortunately, most people who experience statin side effects are women. Women tend to have higher HDL levels than men. Additionally, they typically do not have atherosclerotic plaque until menopause and usually do not develop it after menopause if they undergo estrogen replacement therapy! This gender issue is just one of the problems with laboratory reference ranges that are not adjusted for sex. The total cholesterol values were developed solely from the blood levels of men, who typically have lower HDL levels. Women were excluded from the tests conducted to create this blood panel. For women, I dispel the myth that high total cholesterol predicts heart disease by recommending a Cardiac Calcium Scan to check for plaque. If a woman has no plaque by the age of 50 and is taking estrogen, she is unlikely to develop plaque in the future.  I still test them every 2-3 years to ensure that no metabolic changes have altered their risk, but I don't put much faith in the unreliable cholesterol blood panel. There is another blood test that has deceptive reference ranges: IGF-1 How about the GH-IGF-1 test, the test for Growth Hormone?  IGF-1 is a metabolite of GH that we can measure to determine how much the patient produces.  This hormone aids in healing and replenishing aging cells in patients after their growth is complete.  The healthy normal range with which I was trained, (150-350 MIU), has been changed to an age-adjusted normal that compares a person to others in her age category who had their blood drawn the previous year.  What is wrong with this? Growth hormone (GH) decreases with age and contributes to the declining health people experience as they grow older. Similarly, IGF-1 diminishes with age and illness, which means that the “reference range” essentially reflects that you are “average for the sick individuals who visit Quest to have their IGF-1 levels checked. ” IGF-1 levels can be enhanced through weight loss, testosterone replacement, and an increase in muscle mass. The current reference range does not indicate health or illness; it merely shows whether you fall within the average for your age group. This non-scientific method of determining “health” is widespread in contemporary medicine. By comparing aging individuals to others within the same age group, for hormones that decline with age, based on samples from sick patients who visit a specific lab in the past year, these labs label patients as “healthy” even when they are as ill as other individuals their age who go to that lab! This practice constitutes age discrimination! Regarding hormones, the levels we maintained during our fertile and youthful years correspond to the blood levels indicative of health in all individuals ages. For example: People who check their IGF-1 (Growth Hormone) levels and see a low “52 ng/ml” might feel satisfied that they are within the standard range (50-280 ng/ml). However, they may not realize that this range applies to older, unhealthy individuals, not to healthy young ones (150-350 ng/ml).  This is just one example of the issues that arise when non-medical individuals, who do not monitor these tests regularly, draw conclusions from the numbers.   Some illnesses require more than one blood test for diagnosis If you consider only one of the three tests for diabetes or prediabetes (Fasting Blood Sugar, HbA1c, and Insulin), you cannot self-diagnose as diabetic, prediabetic, insulin resistance or healthy.  Diabetes is a disease that has coincided with the rising number of obese individuals.  Both conditions affect nearly 50% of the American population. Blood tests cannot be interpreted accurately unless a patient has fasted for 12 hours; all three tests should be evaluated. When diagnosing diabetes and insulin resistance, we perform three tests to assess whether a patient has insulin resistance, prediabetes, or diabetes. These tests guide our diagnosis and inform the treatment we provide based on their results. Fasting insulin is a highly misleading test. Over 15 years ago, a significant study was conducted that was believed to change the reference ranges for fasting insulin.  The new range set for normal fasting insulin was less than 10 mIU/ml. By publishing the reference range less than 18 mIU/ml, they miss diagnosing many patients with insulin resistance HBA1C is a test that gives a value of average blood sugar over three months. The results are often used alone to determine prediabetes and diabetes; however, considering all three aspects makes the diagnosis and treatment plan more specific for the patient. FBS (fasting blood sugar) is the third diabetes test. It is generally used as a screening test that prompts the ordering of the other two blood tests; however, some patients exhibit symptoms of diabetes and insulin resistance without having elevated fasting insulin levels. Many medications can raise diabetic test values, causing a patient to seem diabetic when they are actually experiencing a side effect of the drug.  One such medication is Atorvastatin.  The solution is not treating diabetes but rather adjusting the medication.  Hormone tests are especially challenging to interpret, Especially when testing free Testosterone in women Here are the problems with the free Testosterone test itself: Women have extremely low levels of free testosterone and testosterone compared to men. I have been informed by Quest that women's free testosterone levels are not reliable with current methods because they are not always reproducible when a test is conducted twice on the same day. This leads me to believe that hormone levels do not always reflect the actual blood levels of free testosterone and estradiol. The levels of testosterone in women are based on menopausal levels of T. Women have long been thought to not produce testosterone, so the “normal” levels are quite low, and 0 used to be considered normal- until one day I managed to persuade a medical director at Quest to increase it to 0.2! Women's testosterone is influenced by their production of E2 and E1, which inactivate free T. Women vary in how their cells respond to testosterone and estradiol. Receptor sites and their genetic acceptance of hormones can mean that the same blood level of testosterone in both sexes does not produce the same effects in all patients. Some women (and men) are resistant to E2 and T, or to one of the two. This indicates that the hormone-free T level may be optimal for one woman while being ineffective in alleviating any low T symptoms for another. The latter individual is T resistant, and we currently have no means outside of research labs to determine which women are sensitive and which are resistant. This requires that doctors and NPs look beyond typical reference ranges to effectively manage E2 and T replacement for women. Lastly some labs use the total testosterone level through a formula determine the free T. This carries inherent risks of reporting the wrong active level of testosterone. Total and free testosterone blood levels for men, are derived from results of older men, rather than from the blood levels that indicate health and the levels at which men experience no symptoms. This leads men to believe they are normal, even though they are symptomatic, and they can't get treatment. There is no time to discuss the reference ranges for LH, FSH, Estradiol, and Estrone; these topics will be addressed in a future blog. I hope I have encouraged you to review your blood work with your doctor or Nurse Practitioner, and not to act as your own doctor by interpreting your blood tests.

Let's be real—entrepreneurs love the grind. Late nights, early mornings, endless coffee, and pushing the limits to build the dream. But here's the catch: if your heart isn't in peak condition, all that hustle could be cutting your time short.So, how do you level up your business without sacrificing your health?In this episode of The Happy Hustle Podcast, I sat down with Dr. Stefan Waller, a cardiologist turned health coach, to break down real strategies for optimizing heart health—without the fluff. We're talking about preventing heart disease before it even starts, simple nutrition hacks, and the key health metrics every entrepreneur should track.Dr. Waller emphasizes the importance of knowing your numbers. If you don't track your business finances, you'll go broke, right? Same thing with your health—if you don't track your key metrics, your body might be running on borrowed time.Here are two critical numbers you should be checking regularly:1️⃣ LDL Cholesterol (The Silent Killer)

Episode Summary: When it comes to fat loss, there is no one-size-fits-all approach to carbohydrates. In this episode, we dive into how to personalize your carbohydrate intake based on key factors such as your baseline diet, body composition, activity level, and even your unique blood sugar response. By understanding how your body processes carbs, you can fine-tune your intake for sustainable fat loss and optimal energy levels. Before we get started, grab your copy of my new Fat Loss E-Book! Here's the link. And, head over to my new YouTube channel to subscribe and turn on notifications before the new Carb Series kicks off next week.  What You'll Learn in This Episode: ✔ How to assess your baseline carbohydrate intake before making adjustments ✔ Why muscle mass and body fat percentage impact carb tolerance ✔ The role of activity level in determining your optimal carb intake ✔ How health goals (fat loss, performance, hormone balance) influence carb strategy ✔ Why food sensitivities and individual blood sugar responses matter ✔ Practical strategies for tracking and adjusting your carb intake Key Factors to Consider When Personalizing Carb Intake 1. Your Baseline – Where Are You Starting? Before making changes, assess your current carbohydrate intake. Track what you eat for a few days and consider factors like: Blood sugar response (using a glucometer or continuous glucose monitor) Insulin sensitivity (fasting glucose, HbA1c levels) Energy levels and hunger cues

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! New ACP Guidelines Recommend Adding Triptan to NSAID or Acetaminophen for Migraines The American College of Physicians now recommends adding a triptan to NSAIDs or acetaminophen for moderate to severe acute migraines and urges clinicians to initiate combination therapy early. Automated Insulin Delivery Effectively Lowers HbA1c in Type 2 Diabetes  Tandem Diabetes Care's Control-IQ+ automated insulin delivery system led to greater HbA1c reduction than continuous glucose monitoring alone in adults with insulin-requiring type 2 diabetes. FDA Approves Guselkumab (Tremfya) For Crohn's Disease  The FDA approved guselkumab for moderately to severely active Crohn's disease based on phase 3 trial data demonstrating superior efficacy over ustekinumab on endoscopic endpoints. FDA Approves Oral Iptacopan (Fabhalta) as First C3 Glomerulopathy Therapy  The FDA approved iptacopan as the first therapy for C3 glomerulopathy, with phase 3 data showing significant proteinuria reduction and sustained efficacy at 12 months. FDA Approves Vutrisiran (AMVUTTRA) for ATTR-CM  The FDA expanded vutrisiran's approval for cardiomyopathy in transthyretin-mediated amyloidosis, making it the first RNAi therapeutic to reduce cardiovascular mortality and hospitalizations in ATTR-CM.

 In this Episode we shared why Sea vegetables are the most nutritionally dense plants on the planet and the most abundant source of vitamins and minerals in the plant kingdom.  We  highlighted Anti-aging, Energy, and daily nutrition.Guest: Greg Good, the CEO and Founder of FarmaSea and Sea Veg Whole Food Seaweed supplement.Sea vegetables are packed with protein, iodine, fiber and vitamins A, B, C and E in amounts that are 10 to 20 times higher than land vegetables, while some sea vegetables contain more calcium than milk. Sea lettuce has 25 times the iron found in beef. Which is great for people who can't have beef or prefer not to.An 8-week study of 60 Japanese people revealed that fucoxanthin, a substance in brown seaweed, may help improve blood sugar control.Another substance in seaweed called alginate prevented blood sugar spikes in animals after they were fed a high-sugar meal. It's thought that alginate may reduce the absorption of sugar into the bloodstream.A 2023 meta-analysis Trusted Source found that brown seaweed consumption significantly improved blood glucose, glycated hemoglobin (HbA1c), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).Anyone who wants help to feel more natural energy, take a preventative approach to their health, manage the effects of aging, and look to bridge the nutritional gaps currently they're not getting in their daily diet. Check out Superfoodofthesea.com or at 855-627-9929 to ensure that you get the high quality of pure Sea Veg products. Forever Young Listeners for a limited time, you can get 3 bottles of the (90) original Sea veg for $60. Just use the code FY3460 (This is for first time orders only).

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: New drug is looked at for T1D prevention, a new stem cell method is tested for beta cell transplanation without immunosuppresion drugs, the FDA okays the first fast-acting biosimilar insulin, Lilly lowers price of Zepbound, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX New research in type 1 diabetes prevention launches. Nektar Therapeutics and TrialNet will evaluate a drug currently used for exzema for patients with new onset stage 3 type 1 diabetes The drug is RezPeg – that's a shortened version of the name (rezpegaldesleukin)   This will be a study of about 70 adults and children and will launch this year. The new study will use a mixed meal tolerance test (MMTT) to measure the efficacy of rezpegaldesleukin or placebo for preserving C-peptide area under the curve over a 12-month duration comprised of a 6-month treatment period and a 6-month follow-up. Secondary objectives include pharmacokinetics, pharmacodynamics, and additional disease assessments including HbA1c levels and patient insulin requirements. Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. https://www.prnewswire.com/news-releases/nektar-announces-clinical-trial-agreement-to-evaluate-rezpegaldesleukin-in-patients-with-new-onset-type-1-diabetes-mellitus-302383052.html XX NLS Pharmaceutics (NLSP) and Kadimastem announced successful completion of a pre-IND meeting with the FDA for iTOL-102, a potential diabetes treatment. iTOL-102 combines Kadimastem's IsletRx cells (stem cell-derived pancreatic islets) with iTolerance's immunomodulator iTOL-100, aiming to cure Type 1 Diabetes without requiring life-long immune suppression. The treatment was evaluated at the Diabetes Research Institute at the University of Miami School of Medicine, where it demonstrated functional insulin release and disease reversal in animal models. Based on FDA feedback, the companies are updating plans for safety toxicology studies and First-in-Human clinical trials. IsletRx is a clinical-grade product comprising human pancreatic islet-like cells capable of secreting insulin, offering a scalable source of insulin-producing cells to address donor islet shortages. The technology can detect glucose levels and produce required amounts of insulin and glucagon.   XX FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has given a thumbs up to Sanofi's Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk's NovoLog for patients with diabetes. Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial. It is for adults and pediatric patients age 6 and older.     NovoLog and Novo Nordisk's other rapid-acting insulin follow-on Fiasp are among the drugs subject to government price negotiations under the Inflation Reduction Act. The new prices will be enacted at the start of next year. In July 2021, the FDA approved Biocon and Viatris' Semglee (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly's version of the drug, called Rezvoglar (insulin glargine-aglr). https://www.fiercepharma.com/pharma/fda-signs-sanofis-biosimilar-first-novo-nordisks-rapid-acting-novolog XX Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. The company launched 7.5 mg and 10 mg vials of tirzepatide, sold under the brand name Zepbound, which typically cost $599 and $699, respectively. However, they are now available for $499 per month for patients paying without insurance. This applies to the first fill and all refills that are delivered every 45 days. Additionally, the company lowered the prices of the 2.5 mg and 5 mg vials to $349 and $499 per month, respectively. The company, which has seen a significant boost in profits from Zepbound and Mounjaro – essentially the same drug with different FDA-approved uses – announced that the new vials and pricing are exclusively available through the company's self-pay pharmacy, LillyDirect Self Pay Pharmacy Solutions. https://www.bloomberg.com/news/articles/2025-02-25/zepbound-cost-for-vials-cut-to-battle-cheaper-copycats XX Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could reach $102 billion next year, an analysis by Health and Human Services' inspector general found. The findings also come as the Trump administration weighs the fate of a Biden administration proposal that would require Medicare and Medicaid to cover GLP-1s for weight loss. The biggest spikes in usage were for Rybelsus, Novo Nordisk's once-daily GLP-1 tablet, and for the company's weekly injectable Ozempic, whose spending about doubled every year under review. https://www.axios.com/2025/02/25/medicare-spending-surge-diabetes-drugs XX Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up Control IQ for use in adults with Type 2 diabetes. The expanded label was based on data from a pivotal, randomized trial of more than 300 people with Type 2 diabetes, comparing its use to manual multiple daily injections. Tandem said it plans to present the study's results at the annual Advanced Technologies & Treatments for Diabetes meeting scheduled for next month in Amsterdam. https://www.fiercebiotech.com/medtech/tandem-diabetes-care-insulin-dosing-algorithm-nets-fda-clearance-type-2-diabetes XX Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according to a new paper published in Nature Mental Health.   The study reviewed and integrated data from both preclinical and clinical studies to gather evidence on the possible effects of these drugs GLP1s and semaglutide  in conditions such as dementia, substance use disorders, psychotic disorders, mood and anxiety disorders, and eating disorders.     The study found promising but still preliminary evidence that GLP-1RAs could be beneficial over a range of cognitive and mental health disorders. These drugs have shown potential in improving cognition, reducing addictive behavior, and alleviating depression and anxiety. More data from robustly designed studies (i.e., randomized controlled trials) are needed to better understand GLP-1RAs' prospective efficacy and safety profile, especially with long-term use. https://medicalxpress.com/news/2025-02-diabetes-drugs-mental-health-treatment.html XX The FDA  issued draft guidance that includes recommendations to support the development and marketing of safe and effective AI-enabled The guidance, if finalized, would be the first guidance to provide comprehensive recommendations for AI-enabled devices throughout the total product lifecycle, providing developers with an accessible set of considerations that tie together design, development, maintenance, and documentation recommendations to help ensure the safety and effectiveness of AI-enabled devices. FDA is requesting public comment on this draft guidance by April 7. The agency also released draft guidance for the use of AI to support regulatory decision-making for drug and biological products. https://www.mddionline.com/artificial-intelligence/fda-issues-draft-guidance-for-ai-enabled-devices-seeks-public-feedback XX Congrats to Mila Clarke who some of you may know better as Hangry Woman on social. She has developed a great app called Glucose Guide and the Nutrition Assistant portion of that app went live this week. Glucose Guide is a web and mobile app that offers diabetes meal tracking, coaching, resources, recipes and community to those looking for help managing diabetes. MEAL AND BLOOD SUGAR TRACKING FEATURES.

Join us for a fascinating conversation with Dr. Eric Westman, a leading expert in the field of ketogenic diets. With over 25 years of experience, Dr. Westman shares his insights on the power of ketogenic approaches, including his experience using them to improve the health and weight of his own patients for nearly 3 decades. We delve into the science behind these diets, exploring their benefits and potential drawbacks. Dr. Westman also clarifies the connection between carnivore diets and ketogenic diets, offering his perspective and insights. Whether you're curious about keto, considering a carnivore lifestyle, or simply looking to improve your health, this episode is packed with valuable information you won't want to miss! Professor Eric Westman Links: Dr. Westman free diabetes LAB workshop: February 10:

In this Q&A episode, I'm answering some of the most common questions that land in my DMs! From the best ways to support your baby's gut health after a C-section to natural strategies for lowering HbA1c and optimizing metabolic health, I'm covering it all. Plus, I dive into the hot topic of sauna use during pregnancy—what's safe, what's not, and my personal experience. Want your question answered in a future episode? Send me a DM on Instagram!   I TALK ABOUT:  04:00 – Supporting my baby's gut health after a C-section 07:30 – Debunking myths about vaginal seeding and vaginal swabbing for C-section babies 14:00 – The importance of immediate skin-to-skin contact after birth 18:00 – Tiny Health's at-home microbiome test for babies and moms (code: BIOHACKINGBRITTANY) 20:00 – The best probiotics for newborn gut health (Evivo, BioGaia) 23:00 – Introducing prebiotic and probiotic-rich foods when starting solids 26:00 – How to lower HbA1c naturally through nutrition and movement 32:00 – The best supplements for optimizing insulin sensitivity 35:00 – Why sleep and stress management are key to metabolic health 37:00 – Sauna use during pregnancy 42:00 – My personal experience with sauna use while pregnant   SPONSORS: Protect your reproductive health with Leela Quantum Tech's EMF-blocking underwear. Use code: BIOHACKINGBRITTANY for an extra 10% discount on all of their products!   RESOURCES: Optimize your preconception health by joining my Baby Steps Course today! Optimize your preconception health and fertility through my free hormone balancing, fertility boosting chocolate recipe! Download it now! My Amazon storefront LET'S CONNECT: Instagram, TikTok, Facebook Shop my favorite health products Listen on Spotify, Apple Podcasts, YouTube Music

In this Episode we will share why Sea vegetables are the most nutritionally dense plants on the planet and the most abundant source of vitamins and minerals in the plant kingdom.  We will highlight Energy, and daily nutrition.To help us do the heavy lifting we have invited Greg Good, the CEO and Founder of FarmaSea and Sea Veg Whole Food Seaweed supplement.Sea vegetables are packed with protein, iodine, fiber and vitamins A, B, C and E in amounts that are 10 to 20 times higher than land vegetables, while some sea vegetables contain more calcium than milk. Sea lettuce has 25 times the iron found in beef. Which is great for people who can't have beef or prefer not to.An 8-week study of 60 Japanese people revealed that fucoxanthin, a substance in brown seaweed, may help improve blood sugar control.Another substance in seaweed called alginate prevented blood sugar spikes in animals after they were fed a high-sugar meal. It's thought that alginate may reduce the absorption of sugar into the bloodstream.A 2023 meta-analysis Trusted Source found that brown seaweed consumption significantly improved blood glucose, glycated hemoglobin (HbA1c), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).Anyone who wants help to feel more natural energy, take a preventative approach to their health, manage the effects of aging, and look to bridge the nutritional gaps currently they're not getting in their daily diet. Check out Superfoodofthesea.com or at 855-627-9929 to ensure that you get the high quality of pure Sea Veg products.For Forever Young Listeners for a limited time, you can get 3 bottles of the (90) original Sea veg for $60. Just use the code FY3460 (This is for first time orders only).

This week on Fuel for the Sole, we discuss a new research paper about heavy metals found in protein powders, and answer a bunch of listener questions, including:  If athletes have higher HbA1c than the general public  Which electrolytes you should be taking  The importance of third party testing  How to fuel on the bike  A whole lot more!  Want to be featured on the show? Email us at⁠ fuelforthesolepodcast@gmail.com⁠.  This episode is fueled by ASICS and RNWY! Head over to⁠ ASICS.com⁠ and sign up for a OneASICS account. It's completely free and when you sign up you will receive 10% off your first purchase. You also gain access to exclusive colorways on ASICS.com, free standard shipping, special birthday month discounts and more. We've been using RNWY Collagen and loving it. Head over to ⁠https://rnwy.life/⁠ and use code FEATHERS15 for 15% off your purchase. 

Chlorhexidine and Diabetes: Effects of Mouthwash on Periodontal Pathogens and HbA1c Levels By Today's RDH Research Original article published on Today's RDH: https://www.todaysrdh.com/chlorhexidine-and-diabetes-effects-of-mouthwash-on-periodontal-pathogens-and-hba1c-levels/ Need CE? Start earning CE credits today at ⁠⁠⁠⁠https://rdh.tv/ce⁠⁠⁠⁠  Get daily dental hygiene articles at ⁠⁠⁠⁠https://www.todaysrdh.com⁠⁠⁠⁠ Follow Today's RDH on Facebook: ⁠⁠⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠⁠⁠ Follow Kara RDH on Facebook: ⁠⁠⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠⁠⁠ Follow Kara RDH on Instagram: ⁠⁠⁠⁠https://www.instagram.com/kara_rdh/

Ads for Ozempic, Wegovy, and Zepbound are all over our televisions (at least here in the US). But are these injectables really the key to losing weight and keeping it off? In this episode, I'm digging into all of the science surrounding these popular weight-loss drugs, including - the differences between each of them - how they work (and don't work) - the unwanted side effects that come from using these medications - natural ways to increase your body's production of GLP-1 ... and more! --- Show Notes: References: Coursework from Master's in Human Nutrition & Functional Medicine Program at the University of Western States Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Weight Loss Medications: GLP-1 Agonists and How They Work How Much Does Ozempic Cost? With & Without Insurance Zepbound vs. Ozempic: 5 Differences Between These Weekly Injections What Are Incretin Mimetics, and How Do They Affect Weight Loss, Blood Sugar, and Type 2 Diabetes? Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity The Positive Effects of Yerba Maté (Ilex paraguariensis) in Obesity Anti-obesity effects of Yerba Mate (Ilex Paraguariensis): a randomized, double-blind, placebo-controlled clinical trial The effect of psyllium on fasting blood sugar, HbA1c, HOMA IR, and insulin control: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials Soluble fibers from psyllium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial) Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins A High Dose of Dietary Berberine Improves Gut Wall Morphology, Despite an Expansion of Enterobacteriaceae and a Reduction in Beneficial Microbiota in Broiler Chickens Berberine enhances the AMPK activation and autophagy and mitigates high glucose-induced apoptosis of mouse podocytes Curcumin induces secretion of glucagon-like peptide-1 through an oxidation-dependent mechanism --- 135: What You Should Know Before Starting Ozempic Sign up for a 1:1 Discovery Call Join the Compass Method DIY Program Jump inside my Rock the Bloat Minicourse Get my Core-Gi Workout Program with the exclusive listener discount! Join my Brain Rewiring Masterclass You can learn more about me by following on IG @imperfectlypaigewellness or by checking out my blog, freebies, and offers on my website: https://imperfectlypaigewellness.com Please share with #PaigeTalksWellness to help get the word out about the show - and join the Imperfect Health Fam over on Facebook.

Introducing Blood sugar hacks to give you more energy | Glucose Goddess Jessie Inchauspé and Prof. Tim Spector from ZOE Science & Nutrition.Follow the show: ZOE Science & Nutrition Why do some people feel fine eating lots of carbs when others feel energy slumps? Is blood sugar to blame?In this episode, we learn why blood sugar varies so much between people, and the tools to manage these levels. Tim Spector and Jessie Inchauspé (aka the Glucose Goddess) will discuss the latest science around glucose control, what the cool new device on the block – the CGM – can tell us and why blood sugar levels are only one part of the picture of our health.Jessie is a bestselling author and science communicator with a community of over 5 million followers. Tim is a professor of epidemiology at King's College London and ZOE's scientific co-founder.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Mannkind releases info about it's Afrezza pediatric studies, Dexcom launches AI tech with Stelo, Health Canada approves Tandem/Dexcom G7, diabetes drug may help sleep apnea, an app in development to help drivers with T1D and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Mannkid expects to talk to the FDA about Afrezza inhaled insulin for pediatric approval early in 2025. The company just announced six-month results from its Phase 3 INHALE-1 study of kids aged 4-17 with type 1 or type 2 diabetes comparing either inhaled pre-meal insulin or multiple daily injections (MDI) of rapid-acting insulin analog, both in combination with basal insulin. A 26-week extension phase in which all remaining MDI patients were switched to inhaled insulin is ongoing. HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), largely driven by the variability of a single patient who did not adhere to the study protocol. A modified ITT (mITT) analysis, which excluded this subject, did not exceed the predetermined threshold of 0.4% (0.370%), thereby establishing the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. Over 26 weeks of treatment, there were no differences in lung function parameters between the treatment groups, There were no differences between groups or concerns in other safety measures, including hypoglycemia. https://www.medscape.com/viewarticle/inhaled-insulin-benefits-kids-diabetes-too-2024a1000nex   XX Dexcom announces the use of AI for its Stelo platform. The company says the new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. Stelo users will start seeing the features this week. The AI is modeled after Google Cloud's Vertex AI and Gemini models. We'll hear more about this in January – Dexcom will be part of a panel at the Consumer Electronics Show about AI and healthcare. BTW this press release is the first time I've seen what seems to be a new slogan for Dexcom – Discover What You're Made Of. https://www.businesswire.com/news/home/20241217011997/en/Dexcom-Launches-the-First-Generative-AI-Platform-in-Glucose-Biosensing XX Staying with Dexcom, users report that the geofencing issue we reported on seems to be resolved. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn't reinstall or use the app without customer support. With the latest iOS and Android G7 apps, this seems to be resolved. This is according to the folks in the DIY community who first brought it to my attention.   XX Interesting insulin development to watch. Egypt approves EVA Pharma's insulin drug products, which is a collbaration between Eli llly and EVA, an Egyptian company. The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.   Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030. https://www.prnewswire.com/news-releases/lilly-and-eva-pharma-announce-regulatory-approval-and-release-of-locally-manufactured-insulin-in-egypt-302333269.html     XX Can we add treating sleep apnea to the list of applications for terzepatide? That's the generic for Zepbound and Mounjaro. Phase 3 study shows that 10- and 15-milligram injections of Zepbound "significantly reduced the apnea-hypopnea index" among those who have obesity and moderate-to-severe obstructive sleep apnea. Eli Lilly said there was nearly a 20% reduction in weight among those in the trials. The company said it plans to submit its findings to the Food and Drug Administration and other global regulatory agencies beginning mid-year. https://www.aol.com/popular-weight-loss-drug-could-131507702.html   XX Health Canada okays Tandem's tslim X2 with Dexcom G7 and G6 making it the first and only insulin pump in Canada that is integrated with both Dexcom sensors. Now, t:slim X2 users in Canada can experience even more choice when it comes to CGM compatibility, along with the option to spend more time in closed loop with Dexcom G7's 30-minute sensor warm-up time, faster than any other CGM on the market.3 In addition, t:slim X2 users who pair Dexcom G7 with an Apple smartwatch4 can see their glucose numbers directly from their watch without having to access their pump or smartphone4. Tandem will email all in-warranty t:slim X2 users in Canada with instructions on how to add the new compatibility feature free of charge via remote software update. t:slim X2 pumps pre-loaded with the updated software will begin shipping to new customers in early January 2025.   To check coverage and start the process of getting a Tandem insulin pump, please visit tandemdiabetes.ca. https://www.businesswire.com/news/home/20241210731189/en/Tandem-tslim-X2-Insulin-Pump-Now-Compatible-with-Dexcom-G7-CGM-in-Canada XX A federal jury on Tuesday awarded Insulet $452 million in its patent skirmish with EOFlow over insulin patch pumps. The jury awarded Insulet $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages for willful and malicious misappropriation. A judge has not yet entered a judgment on the decision. Insulet filed a lawsuit in the U.S. District Court for the District of Massachusetts in 2023, claiming EOFlow copied patented components of its Omnipod insulin pumps. In October 2023, the Massachusetts district court issued a preliminary injunction against EOFlow. Following that decision, Medtronic called off plans to buy EOFlow for about $738 million.   A federal appeals court later overturned the preliminary injunction, and EOFlow resumed selling its devices in Europe. The company recently defended against a separate injunction filed by Insulet in Europe's Unified Patent Court, according to Korea Biomedical Review, an online English newspaper based in Seoul, South Korea.   The Massachusetts jury found this week that EOFlow and CEO Jesse Kim, as well as two of three former Insulet employees who were named as defendants in the lawsuit, misappropriated Insulet's trade secrets.   Insulet CEO Jim Hollingshead said the company is “extremely pleased with the jury's verdict.” EOFlow did not immediately respond to a request for comment. https://www.medtechdive.com/news/insulet-eoflow-jury-verdict-patent-lawsuit/734745/ XX A tele-education program for health care providers who treat people with diabetes resulted in significant improvements in patient outcomes, including better blood sugar levels and increased use of medical devices to manage the disease, a University of Florida study finds. Led by researchers in the UF College of Public Health and Health Professions and the UF College of Medicine, the program used the Extension for Community Health Care Outcomes model, which has been adopted worldwide to train clinicians who treat patients with a variety of conditions. Known as Project ECHO, this is one of the first to demonstrate patient benefits for the program in a large, randomized trial. The findings appear in the journal Diabetes Care. https://ufhealth.org/news/2024/clinician-training-program-leads-to-better-outcomes-for-patients-with-diabetes XX New app under development to make driving safer for people with diabetes. Diabetes Driving Pal says it will use CGM data and guide you while you are driving without any annoying alerts. Guidance/suggestions will be on your car dashboard so that you don't have to look at phone and it will be very individualized and actionable. In a study last year, ~70% of people have reported (5% reported accident) to have at least one low blood sugar while driving and most reported that CGM alerts were not enough to protect them. We are hoping to start beta testing in a few months. We are trying to raise the fund to develop this product. We need your support. For more information, please visit: https://lnkd.in/gTDhnDc4 XX I'm also going to link to the top ten most read diabetes and endocrinology stories of 2024 from Medscape. This is almost all GLP-1 related.. and mostly for people with type 2. https://www.medscape.com/viewarticle/icymi-top-10-diabetes-endocrinology-stories-2024-2024a1000n6u?&icd=login_success_email_match_fpf XX That's it for the last In the News of 2024! Don't miss out episode next week with a look ahead to what we're watching in 2025. I'm SS I'll see you back here soon…

In this Episode we will share why Sea vegetables are the most nutritionally dense plants on the planet and the most abundant source of vitamins and minerals in the plant kingdom.  We will highlight Energy, and daily nutrition.]To help us do the heavy lifting we have invited Greg Good, the CEO and Founder of FarmaSea and Sea Veg Whole Food Seaweed supplement.Sea vegetables are packed with protein, iodine, fiber and vitamins A, B, C and E in amounts that are 10 to 20 times higher than land vegetables, while some sea vegetables contain more calcium than milk. Sea lettuce has 25 times the iron found in beef. Which is great for people who can't have beef or prefer not to.An 8-week study of 60 Japanese people revealed that fucoxanthin, a substance in brown seaweed, may help improve blood sugar control.Another substance in seaweed called alginate prevented blood sugar spikes in animals after they were fed a high-sugar meal. It's thought that alginate may reduce the absorption of sugar into the bloodstream.A 2023 meta-analysis Trusted Source found that brown seaweed consumption significantly improved blood glucose, glycated hemoglobin (HbA1c), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).Anyone who wants help to feel more natural energy, take a preventative approach to their health, manage the effects of aging, and look to bridge the nutritional gaps currently they're not getting in their daily diet.Check out Superfoodofthesea.com or at 855-627-9929 to ensure that you get the high quality of pure Sea Veg products.For Forever Young Listeners for a limited time, you can get 3 bottles of the (90) original Sea veg for $60. Just use the code FY3460 (This is for first time orders only).

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours This week on the podcast Mikki speaks to Dr. Michelle Woolhouse, a  multifaceted physician whose work blends the best of western medical training with the insights of integrative and complementary therapies. Michelle is a general practitioner with qualifications in psychotherapy, acupuncture, hypnotherapy, and integrative medicine. She's also the co-founder of Vively, a platform designed to empower people to take control of their metabolic health through cutting-edge tools like continuous glucose monitoring (CGM).They unpack the journey that brought Michelle to focus on whole-person health. From her early days as a western-trained doctor to the experiences that shaped her understanding of holistic care, Michelle shares powerful insights about how metabolic health underpins not only physical wellness but also mental health, longevity, and quality of life.They discuss the importance of recognising early warning signs of poor metabolic health—long before traditional markers like HbA1c flag a problem. Michelle also explores how lifestyle factors such as stress, sleep, and diet intersect with metabolic health and how her work with Vively is reshaping how people engage with their health through personalised insights and actionable data.If you've ever wondered how technology can bridge the gap between prevention and treatment, or how we might transform mainstream healthcare to prioritise proactive care over reactive care, this episode is for you.Dr. Michelle Woolhouse, an experienced holistic doctor, who integrates the realms of psychotherapy, neuroscience, and integrative functional medicine to guide you on your path to optimal well-being. As the author of "The Wonder Within" and a highly sort after keynote speaker, Dr. Woolhouse offers a transformative approach to healthcare.  Dr. Michelle's specialty differs from the typical medical encounter or standard coaching session, as she dedicates extensive time to each individual, uncovering root cause insights into your unique health journey. Her practice recognises the interconnectedness of mind, body, environment and personal beliefs, guiding you towards holistic wellness and personal empowerment.Drawing on her expertise in psycho-neuro-immunology, nutrition and functional testing, Dr. Woolhouse navigates the intricate language of the brain and body to empower people to better health and outcomes. Through a compassionate approach she supports you in addressing underlying challenges and harnesses the power of mind-body medicine to facilitate personal and professional flourishing.Michelle https://www.drmichellewoolhouse.com/pages/aboutVively app https://www.vively.com.au/  Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

Susan Harris is a television host, reality docuseries guest, former teacher, and encourager. She has reversed Type 2 diabetes, dropping her HbA1c from over 13 to close to 5, using select foods, walking, and a positive mindset, and is passionate about helping others overcome disbetes. Susan has written several books aming them the winning Little Copper Penny series and her memoir Touched By Eternity. Born on the beautiful island of Trinidad, Susan now calls the lush prairies of Saskatchewan home. Susan's family includes her husband, daughter and son-in-law, and the beloved cats. Visit her website at SusanHarris.ca   ✅ Dr Chaffee's website: www.thecarnivorelife.com ✅Join my PATREON for early releases, bonus content, and weekly Zoom meetings! https://www.patreon.com/AnthonyChaffeeMD ✅Sign up for our 30-day carnivore challenge and group here! https://www.howtocarnivore.com/ ✅Stockman Steaks, Australia Discount link for home delivered frozen grass-fed and grass finished pasture raised meat locally sourced here in Australia! Use discount code "CHAFFEE" for free gift with qualifying orders! http://www.stockmansteaks.com.au/chaffee ✅ 60-minute consultation with Dr Chaffee https://calendly.com/anthonychaffeemd/60-minute-consultation   Sponsors and Affiliates: ✅ Brand Ambassador for Stone and Spear tallow and soaps referral link https://www.stoneandspeartallow.com/?ref=gx0gql8b Discount Code "CHAFFEE" for 10% off ✅ Carnivore t-shirts from the Plant Free MD  www.plantfreetees.com ✅THE CARNIVORE BAR: Discount Code "Anthony" for 10% off all orders!   https://the-carnivore-bar.myshopify.com/?sca_ref=1743809.v3IrTuyDIi ✅Schwank Grill (Natural Gas or Propane) https://glnk.io/503n/anthonychaffeemd $150 OFF with Discount Code: ANTHONYMD ✅X3 bar system with discount code "DRCHAFFEE" https://www.kqzyfj.com/click-100676052-13511487 ✅Cerule Stem cells https://DrChaffee.cerule.com ✅CARNIVORE CRISPS: Discount Code "DRCHAFFEEMD" for 10% off all orders! www.carnivorecrisps.com ✅Shop Amazon https://www.amazon.com/shop/anthonychaffeemd?ref=ac_inf_hm_vp   And please like and subscribe to my podcast here and Apple/Google podcasts, as well as my YouTube Channel to get updates on all new content, and please consider giving a 5-star rating as it really helps!   This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Music Credit: Music by: bensound.com License code: MPTEUCI8DAXJOKPZ Music: bensound.com License code: FJQPPMCJLHEOYGQB Music: Bensound.com/royalty-free-music License code: KQAKMWSXIH3MJ4WX Music I use: https://www.bensound.com License code: 58NN4QOSKWJ7ASX9   

In part two of our prediabetes series, hosts Jessica Jones and Wendy Lopez tackle the burning question: How long does it take to reverse prediabetes? We discuss whether it's possible to reverse prediabetes permanently and explore the essential strategies, key milestones, and success factors involved. From food choices and swaps to exercise plans and other lifestyle changes, we break down the steps you can take to manage and potentially reverse prediabetes. Learn about the importance of reduced HbA1c levels, lowered fasting blood glucose levels, and enhanced insulin sensitivity as key indicators of progress. We also highlight the role of working with a dietitian to track goals, milestones, and overall progress!  Our two simple asks to help us continue a free show: Rate on iTunes or Spotify -  it literally takes two seconds Review - if you love the show, please leave a review on iTunes Diabetes & Prediabetes Nutrition Counseling Are you living with diabetes or prediabetes and seeking support from a Registered Dietitian Nutritionist covered by insurance? Visit diabetesdigital.co to sign up for personalized, one-on-one nutrition counseling with one of our culturally aware and weight-inclusive Diabetes Dietitians today!For additional resources and shownotes, visit diabetesdigital.co/podcast

Discover my premium podcast, The Aliquot Learn how to choose the right omega-3 supplement in my free 13-page guide Exercise, meal timing, and sleep are three powerful tools for optimizing metabolic health, a key factor in healthy aging. Even slightly elevated blood glucose levels, but within the "normal" range, can contribute to brain atrophy in areas linked to aging and neurodegeneration. Long-term glucose elevations (high HbA1c) also promote harmful compounds that stiffen blood vessels, reduce heart flexibility, and raise cardiovascular risk. In this episode, recorded at the American Academy of Anti-Aging Medicine conference in Palm Beach, Florida, I provide practical, science-backed protocols on how to implement HIIT, circadian-timed eating, and optimized sleep strategies to dramatically improve metabolic health and protect against these harmful effects.  Timestamps: (00:00) Introduction (04:25) Why HIIT outshines zone 2 for improving metabolic health (06:46) The signaling role of lactate production by muscle (09:33) Optimal HIIT conditions for improving body composition (10:36) How vigorous exercise repairs dysfunctional mitochondria (14:27) HIIT vs. zone 2 for mitochondrial biogenesis (16:09) Evidence-based HIIT protocols (17:46) Why "exercise snacks" are a crucial pre- and post-mealtime activity (19:50) The mortality benefits of short exercise bursts (23:08) Why late-night eating is detrimental (27:37) Can high glucose levels accelerate brain atrophy? (28:30) How circadian misalignment affects postprandial glucose (29:46) Metabolic health benefits of time-restricted eating (32:24) Why early eating is better for metabolic health (34:48) Why losing sleep for 3 nights mimics type 2 diabetes (36:58) Why less than 7 hours of sleep increases type 2 diabetes risk (37:44) Why chronically high blood glucose damages cardiovascular health (39:39) What 4 hours of sleep for 4 nights does to insulin signaling (40:44) Why short sleep facilitates obesity (42:03) The checklist for good sleep hygiene (45:37) Can 1 hour of extra sleep help you lose weight? (46:47) Cognitive behavioral therapy for insomnia (CBT-I) (48:22) How HIIT improves metabolic health when sleep-restricted (50:55) Can HIIT ameliorate the mortality risk from poor sleep? Show notes are available by clicking here Watch this episode on YouTube

Modern medicine has long considered many neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease to be immutably linked to the fate of certain unlucky individuals through yet-poorly understood genetic mechanisms. But increasingly, we are seeing evidence that some of our lifestyle choices, including our diet, physical activity, and relationships, may play a significant role in the development of, or protection against, these diseases. Our guest on this episode, David Perlmutter, MD, is a neurologist and writer whose immensely popular books, including Grain Brain: The Surprising Truth About Wheat, Carbs, and Sugar — Your Brain's Silent Killers (2013), discuss why diets low in refined carbohydrates and high in fats, in addition to foods that nurture a healthy gut microbiome, may prevent cognitive decline. Over the course of our conversation, we discuss Dr. Perlmutter's path from conventional neurology to moving towards a more functional and holistic approach to treating brain disorders, the importance of metabolic health in maintaining our cognitive capacities, how Dr. Perlmutter responds to critics of his non-conventional medical advice, why nutrition science is riddled with messy and conflicting findings and how we can better navigate through it all, what clinicians can do to better help their patients live well, and more. Note: Some of Dr. Perlmutter's ideas and recommendations have been the subject of debate and controversy within the medical community. While we believe in fostering open dialog and exploring diverse perspectives, the views expressed in this episode are those of Dr. Perlmutter and do not necessarily reflect the views or endorsements of this podcast. We encourage listeners to critically evaluate the information presented and work with qualified healthcare professionals when making any changes to their health and wellness routines.In this episode, you'll hear about: 3:11 - Dr. Perlmutter's transition from conventional neurology to what he calls “preventative” neurology8:43 - Dr. Perlmutter's views on what constitutes a “disease” and the role of the doctor. 19:08 - Emerging science on the importance of metabolic health on brain health 25:17 - How scientific studies on preventative health can be (and have been) designed 34:56 - Why Dr. Perlmutter prioritizes health markers (such as HbA1c) over specific dietary recommendations when working with patients42:21 - Dr. Perlmutter's views on GLP-1 antagonists such as Ozempic and Mounjaro50:36 - How Dr. Perlmutter has dealt with critics of his workDr. David Perlmutter is the author of eight books. Dr. Perlmutter can be found on Twitter/X at @davidperlmutter. Visit our website www.TheDoctorsArt.com where you can find transcripts of all episodes.If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2024